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Abstract 
Stroke is one of major causes of death, and ischemic stroke attributes to approximately 87% of 
all strokes. Our lab has previously shown that during an ischemic insult, adenosine A1 receptor 
(A1R) activation in the rat hippocampus leads to AMPA receptor (AMPAR) downregulation 
and persistent synaptic inhibition. This persistent synaptic depression could contribute to 
neuronal damage, as neurons require constant excitatory inputs. Moreover, we observed an 
adenosine-induced post-hypoxia synaptic potentiation (APSP) in rat hippocampal CA1 field 
potential recordings. Hypoxia-induced cell death and APSP were significantly reduced when 
rat hippocampal slices were pretreated with either A1R or A2AR antagonist, indicating a 
potential interaction between A1Rs and A2ARs through yet unknown mechanisms. This study 
further explores the role of glutamate receptors in the generation of APSP through adenosine 
signalling. We hypothesize that hypoxia induces A1R-mediated, dynamin (a GTPase regulating 
endocytosis)-dependent internalization of A1Rs and GluA2/GluA1 AMPARs, which is then 
followed by an A2AR-mediated upregulation of these AMPARs, which is a prerequisite for full 
expression of APSP. Electrophysiology studies demonstrated that synaptic transmissions and 
APSPs in the rat hippocampal CA1 region are mostly mediated by AMPAergic mechanisms, 
instead of NMDA receptors, and that these required both A1R and A2AR signalling cross-talk. 
To determine whether Ca2+-permeable AMPARs (CP-AMPARs) underlie APSP, I performed 
experiments to test the effects of selective CP-AMPAR antagonists on APSP levels, including 
NASPM, IEM 1460 and Philanthotoxin-74. Application of the CP-AMPARs antagonists at the 
early phase of hypoxic stimulation blocked the generation of APSPs, whereas no attenuated 
effects were observed when applied after the expression of APSPs. In contrast, the clinically 
approved anti-seizure drug Perampanel, which is a non-competitive AMPAR antagonist, 
blocked the generation of APSP. Surprisingly, all CP-AMPAR antagonists tested were effective 
in preventing hypoxia-induced hippocampal neuronal damage during the early phase of 
hypoxic stimulation, but Perampanel was the only compound that prevented neuronal damage 
during normoxic brain slice reperfusion. Additional studies of leukocyte-specific protein1 
(LSP1) knockout mice also revealed a potential contribution of LSP1 to altering synaptic 
plasticity during hypoxia-reperfusion injury models. In particular, LSP1 may regulate the levels 
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of synaptic depression and CP-AMPARs during A1R stimulation in hypoxic conditions. 
Collectively, this study has provided further evidence for CP-AMPARs’ role in delayed 
hippocampal injury, which involves both A1Rs and A2ARs, and reveals GluA2-lacking 
AMPARs as a potential target for designing neuroprotective drugs in the late stage 
neurodegeneration related to hypoxia/ischemia. 
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Introduction 
 
1.1 Hypoxia and Ischemic Stroke 
There are approximately 62,000 strokes occurring in Canada each year, and almost half of 
Canadians either experienced it themselves or have had a close family member or friend who 
suffered from a stroke. More than 400,000 Canadians experience long-term disability from 
stroke, and this number will likely double in the next 20 years (Stroke Report 2017). Ischemic 
stroke is a common form which accounts for about 80% of all strokes. Hypoxia has been 
frequently observed after stroke and it leads to multiple detrimental outcomes. Severe hypoxia 
leads to rapid decrease in oxygen level, which can result in permanent damage to the neuronal 
system in a short period of time (Ferdinand and Roffe 2016). Observations in clinical trials 
have shown that hypoxia in the brain can cause short-term memory deficits, difficulty in 
judgment and inability to accomplish complex tasks (Cooper et al. 2015; Komiyama et al. 
2015).Long-term influence of hypoxia are more widespread in the brain and should be taken 
into serious consideration. In older adults, hypoxic injury in the basal ganglia can result in 
seizures and movement disorders (Howard et al. 2011). Brain hypoxia-ischemia is now a 
common disorder along with a high probability of morbidity in the elderly, often resulting in 
severe stroke (Hung et al. 2017). Functional outcomes of ischemic injury in the brain is not 
predicted well compared to other tissues. Although current knowledge of the biochemical and 
physiological bases of the hypoxia-induced brain damage is well studied, the reason behind 
this unique vulnerability of the brain to stroke still warrants further investigations (Gooshe et 
al. 2015; Payabvash et al. 2011). The human brain is specifically vulnerable to ischemic insults 
since it is an intrinsically, metabolically active organ yet contains virtually no O2 reserve. One 
of the early consequence of hypoxia-ischemia is energy failure, which leads to abnormal ion 
channel activities. Decrease of Na+ gradients after hypoxia will trigger accumulation of 
extracellular glutamate, which will result in overstimulating glutamate receptors and 
neurodegeneration (Dong et al. 2009; Lai et al. 2014; Ribeiro et al. 2010; Schauwecker 2010). 
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1.2  Stroke and Adenosine 
Adenosine has a crucial role in the central nervous system (CNS). There is an inhibitory effect 
of adenosine on the neurotransmission and plays a neuroprotective role to the CNS in certain 
conditions (Sperlágh and Vizi 2011). Therefore, the importance of studying the generation and 
release of adenosine in the human brain has been highlighted by neuroscientists. As an 
endogenous purine nucleoside, adenosine showed its significance in regulating multiple 
physiological processes, such as promoting sleep and suppressing arousal (Huang et al. 2014; 
Maximino et al. 2011; Porkka-Heiskanen and Kalinchuk 2011). In the healthy brain, the 
expression of extracellular adenosine is relatively low, but rapidly increases following hypoxic-
ischemic insult in vitro. For example, in the rat stroke model when animal suffered from short 
period ischemia (10 to 15 minutes), the level of extracellular adenosine in the rat hippocampal 
slices are accumulated by around 20 µM (Latini et al. 1999). Electrophysiological studies in 
the hippocampal slices have shown that adenosine inhibit neurotransmission in the rat CA1 
region and neuronal excitability was also attenuated (Sperlágh and Vizi 2011). In early studies, 
scientist believed that adenosine and adenosine A1 and A2A receptors could develop into 
potential therapeutic targets for stroke patients (Kitagawa et al. 2002; von Lubitz 1999; Pedata 
et al. 2007). However, considering the large scale of the expression of adenosine receptors in 
the CNS and their overall effect on the human body, adenosine-based therapies have 
encountered a great deal of difficulties. Although some studies have observed that early 
application of adenosine (i.e., at the time of stroke) reduces neuronal damage, clinical 
administration of adenosine could cause decreased blood pressure and respiratory alkalosis 
(Kitagawa et al. 2002; Layland et al. 2014). Even with the observation that adenosine may have 
neuroprotective effects in animal models, accurate administration is still a prerequisite since 
adenosine has a short window of efficacy. Additionally, adenosine has a comparable short half-
life (less than 15 seconds) in human plasma and it will decrease blood brain barrier permeability 
(Pardridge et al. 1994), which presents great difficulties in utilizing adenosine in targeted 
delivery during clinical applications. Finally, administration of adenosine has opposing effects 
on different adenosine receptors, due to their different functions and diverse distribution in the 
CNS, which brings more difficulties to its application in clinical trials.  
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1.2.1 Adenosine and Adenosine Receptors 
As an important neuroeffector, the functions of adenosine in the CNS are regulated by several 
adenosine receptors. There are four types of G-protein coupled receptors in the adenosine 
receptor family, with the names of A1, A2A, A2B, and A3 receptors (A1Rs, A2ARs, A2BRs, 
and A3Rs). A1 and A3 were found to couple to inhibitory G proteins, whereas A2A and A2B 
were found to couple to stimulatory G proteins (Sheth et al. 2014). Among the four receptors, 
A1R is not only the most widely expressed receptor in the brain, but also has the highest affinity 
for adenosine (Ribeiro and Sebastio 2010). Highly expressed A1R contributes to the reduction 
of neurotransmission through elevated adenosine in the hippocampus and regulates many 
aspects of the physiological processes involved in neuronal excitability and synaptic plasticity. 
A1R activation has shown to be controversial in both in vivo and in vitro animal models of 
ischemic strokes (Manjunath and Sakhare 2009). Some studies using A1R knockout mice 
showed no significant alteration in neuronal damage induced by global ischemia when 
compared to studies of wild-type mice. Additionally, pre-treatment of A1R antagonist 8-CPT 
at the onset of global ischemia aggravated damage (Olsson et al. 2004). However, our lab 
showed that in hippocampal slices, decreased synaptic transmission and neurodegeneration in 
the CA1 region caused by 20-min hypoxia treatment were attenuated by the application of A1R 
antagonist DPCPX (Stockwell et al. 2016). Moreover, DPCPX also showed a beneficial effect 
during the recovery period after the treatment of hypoxia or prior to administration of a 
selective A1R agonist in vivo (Stockwell et al. 2016, 2017). These results indicated that A1R 
antagonists could have a detrimental or beneficial effect in hypoxia at the neuronal level 
depending on the time of administration (i.e., chronic vs. acute). Although some studies 
suggested that acute stimulation of A1R has neuroprotective effect by decreasing synaptic 
transmission (Williams-Karnesky and Stenzel-Poore 2009), chronic downregulation of A1R 
during post-stroke in animal stroke model or after chronic A1R-agonist stimulation has been 
proven to be contributory for the ischemia-induced insults and impaired long term potentiation 
(LTP) (Chen et al. 2014, 2016). A2ARs are also widespread in the brain (concentrated in basal 
ganglia) with a lower density compared to A1R; it also has a relatively high affinity for 
adenosine. In opposition to A1R, up-regulation of A2ARs are observed in brain after ischemia 
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and researches have justified the importance of A2AR antagonists as potential neuroprotective 
treatment in ischemic stroke, Alzheimer’s and Parkinson’s disease (Casetta et al. 2014; de Lera 
Ruiz et al. 2014; Paterniti et al. 2011; Pedata et al. 2007; Reyhani-Rad and Mahmoudi 2016; 
Stockwell et al. 2017). Since A2BRs and A3Rs have low abundance in the brain (Garcia et al. 
2014), the role of these two receptors have received considerably less attention.  
 
1.2.2 Potential Cross Talk Between Adenosine A1 and A2A receptors 
The mechanism by which adenosine modulates synaptic transmission in hypoxic/ischemic 
injury remains poorly resolved. Elevation of extracellular adenosine in the hippocampus during 
ischemia or hypoxia stimulates both A1Rs and A2ARs, and adenosine-mediated 
neuroprotection or neurodegeneration is due to A1R and A2AR stimulation, respectively 
(Stockwell et al. 2017). A1R activation inhibited glutamatergic synaptic transmission mainly 
through presynaptic inhibition of glutamate release, while A2ARs have been shown to facilitate 
glutamatergic synaptic transmission. Therefore, some reports in the past suggested that 
stimulating A1R and inhibiting A2AR may have neuroprotective effects during ischemia 
(Sweeney 1997; Thauerer et al. 2012). Although at the onset of neuronal injury, A1R activation 
attenuates brain damage, A1R is downregulated in chronic noxious situations. Conversely, 
A2ARs are up-regulated in noxious brain conditions (Cunha 2005) and A2AR antagonists have 
proved to be potential neuroprotective agents in multiple neurodegenerative diseases (Casetta 
et al. 2014; de Lera Ruiz et al. 2014; Pedata et al. 2007; Reyhani-Rad and Mahmoudi 2016). 
Our lab reported that hippocampal A1Rs and excitatory AMPA receptors (AMPARs) are 
downregulated while A2ARs are upregulated after a 20-min hypoxic insult or focal cortical 
ischemia using a pial vessel disruption (PVD) procedure (Chen et al. 2014; Stockwell et al. 
2016). Moreover, A1Rs and AMPARs are physically coupled, whereas A2ARs and AMPARs 
are not (Chen et al. 2014). Following hypoxia during normoxic washout, we observed A2AR-
dependent synaptic potentiation (Stockwell and Cayabyab, unpublished) and therefore 
hypothesized that A1R stimulation is required for subsequent adenosine-induced post-hypoxia 
synaptic potentiation (APSP). Specifically, we found that a 20-min hypoxia treatment followed 
by 45-min normoxic washout/reperfusion produced elevated APSP (150-160%), which was 
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abolished by pre-treatment with either DPCPX (100 nM), an A1R antagonist, or SCH 442416 
(5 nM), an A2AR antagonist. Accordingly, using propidium iodide to label damaged cells, 
hypoxia alone caused significant neuronal death, which was significantly reduced by pre-
incubation in either DPCPX or SCH 442416. These results suggest that both A1R and A2AR 
are involved in the APSP generation we observed, as well as the neurodegeneration caused by 
hypoxia treatment in the rat hippocampal CA1 region, suggesting that the traditional idea of 
A1Rs and A2ARs as individual parallel signalling systems need to be revised. 
 
1.3 Stroke and Glutamate receptors 
Excitotoxicity is a leading cause of central neuronal loss in noxious brain conditions. After 
global ischemia, elevated extracellular glutamate was observed in the CNS, which is believed 
to be important to the biological processes which leads to the impairment of post-hypoxia brain 
tissue. A few glutamate receptors are discovered to regulate this excitotoxicity, including 
NMDA and AMPA receptors (NMDARs, AMPARs) as well as kainate receptors.  
At the early stage of hypoxia, excitotoxicity and the excessive load of calcium are two main 
factors towards neurodegeneration. (Annunziato et al. 2007). Glutamate, serves as the most 
widely expressed neurotransmitter, accumulates in the extracellular space due to energy and 
ion pump failure.  
 
The accumulation of glutamate triggers prolonged stimulation of AMPARs and NMDARs, 
which will result in dramatic enhancement of Ca2+ and Na+ influx in neurons. In studies using 
rat models of several neurological disorders, such as epilepsy, ischemic stroke and Parkinson’s 
Disease, scientists believed that glutamatergic synapse is the potential site for neuroprotective 
drugs to target. (Kostandy 2012; Lai et al. 2014; Schauwecker 2010; Traynelis et al. 2010). 
Although scientists have believed that NMDAR and AMPAR antagonists have neuroprotective 
effects in animal ischemic stroke models for nearly three decades (Meldrum 1990), numerous 
clinical trials targeting NMDARs and AMPARs have been disappointing in ischemic stroke 
patients (Ginsberg 2009; Hoyte et al. 2004; Ikonomidou and Turski 2002). Preclinical data have 
suggested that protection of neurons induced by NMDAR antagonists is most effective if they 
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are applied near the onset of the ischemic stroke. If the antagonists were applied after the onset, 
the neuroprotective effect will be diminished with time. The protective effects usually 
disappears at 1.5-2 hours after the onset (Lipton 2004). NMDAR antagonist like Selfotel has 
been proved that it has little neuroprotective towards acute ischemic stroke. Moreover, if 
Selfotel were applied in the first month on patients with severe ischemic stroke, it might lead 
to a higher rate of death. (Davis et al. 2000).Clinical trials with the application NMDAR 
antagonists in ischemic stroke and brain injury have shown little therapeutic benefit (Hoyte et 
al. 2004; Ikonomidou and Turski 2002; Moretti et al. 2015; Roesler et al. 2003). AMPAR 
antagonists were also proposed to be useful neuroprotective drugs (Constals et al. 2015; 
Frampton 2015; Nayak and Kerr 2013; Whitehead et al. 2017). Competitive AMPAR blockers 
such as 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)qui-noxaline (NBQX), showed robust 
neuroprotection in several animal stroke models (Filliat et al. 1998; Meden et al. 1993). 
Nonetheless, due to their side effects and difficulty in drug delivery, their applications in 
clinical trials have also been disappointing (Buchan et al. 1993).  
 
1.3.1 AMPA receptors 
AMPA receptor is an important inotropic glutamate receptor in the CNS. AMPARs express in 
the neurons and glial cells, which mainly regulates fast-excitatory synaptic transmission 
(Traynelis et al. 2010). There are four subunits for assembling AMPARs, GluA1, GluA2, 
GluA3 and GluA4. In the hippocampal CA1 regions, the AMPARs containing GluA1-GluA2 
heteromers are most abundant (Lu et al. 2009). CA1 region is crucial to memory and the 
induction of LTP is mainly regulated by phosphorylation of GluA1 during the recruitment of 
AMPARs to the synapses (Zamanillo et al. 1999). Meanwhile, GluA2 is regulating AMPAR 
endocytosis and long-term depression (LTD). Also, if an AMPAR contains at least one GluA2 
subunit, it will prevent calcium form entering the cells. Although a large portion of AMPAR in 
the CNS is GluA2-containing AMPARs, GluA2-lacking AMPAR has also shown its 
importance in the hippocampus, habenula and cortex (Wright and Vissel 2012). Since AMPARs 
mainly regulates fast synaptic neurotransmission in the hippocampus, the precise regulation of 
AMPARs has proved to be important in investigating synaptic plasticity and neurotransmission. 
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Multiple studies on the regulation of GluA2-lacking AMPARs have revealed their importance 
in neurological diseases such as ischemic stroke, epilepsy, Parkinson’s and Alzheimer’s 
Disease (Berridge 2011; Chang et al. 2012; Gomes et al. 2011; Weiss 2011; Whitehead et al. 
2017). During ischemic stroke, GluA2 is downregulated, which leads to AMPAR-regulated 
accumulation of calcium and zinc influx (Noh et al. 2005). Studies on the effects of GluA2-
lacking AMPAR antagonists have shown reductions of post-ischemic Zn2+ accumulation and 
neuronal death in the brain (Liu et al. 2004), which demonstrated the importance of GluA2-
lacking AMPARs in ischemic stroke. Some preclinical data indicated that AMPA/kainate 
receptor blockers have better neuroprotective effects when compared to NMDAR blockers 
during ischemic conditions (Dhawan et al. 2011; Ikonomidou and Turski 2002; Lau and 
Tymianski 2010; Traynelis et al. 2010). The neuroprotective effect might due to the blockade 
of GluA2-lacking AMPARs, which indicates that the presence of GluA2-lacking AMPARs are 
associated with this hypoxia induced neurodegeneration (Talos et al. 2006).  
 
1.3.2 NMDA receptors 
N-methyl-D-aspartate receptor (NMDAR) is another important receptor which regulates 
neurotransmission and synaptic plasticity in the CNS. NMDARs contains three kinds of 
subunits, GluN1, GluN2 and GluN3 (Traynelis et al. 2010). Similar to AMPAR, NMDAR is 
another crucial Ca2+-permeable receptor implicated in the process of excitotoxicity. Early 
studies have suggested that blockade NMDA receptor may protect neurons during ischemic 
insults  (Ikonomidou and Turski 2002; Meldrum 1990; Simon et al. 1984), which intrigued 
neurologists to seek out solutions for ischemic stroke from NMDAR antagonists. During 
ischemic stroke, large Ca2+ influx occurs in the hippocampal CA1 region, which leads to 
neurodegeneration and cell death (Tymianski and Tator 1996). Administration of MK-801, a 
NMDA receptor antagonist, attenuates Ca2+ influx during ischemia, however, has little effect 
in preventing cytotoxic intracellular rises in Ca2+ concentrations during post-ischemia period 
(Silver and Erecińska 1992). After the onset of hypoxia induced stroke, glutamate is 
accumulated on the brain, however, the damage could last for days. This might explain the 
failure of NMDAR antagonist based drugs since they are ineffective in the delay 
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neurodegeneration (Albers et al. 1999; Davis et al. 2000). Also, more focus on non-
glutamatergic-induced mechanisms of neurotoxicity warrant further investigation. 
 
1.3.3 GABA receptors 
Gamma-amino- butyric acid (GABA) mediates inhibitory neurotransmission in the CNS and 
acts by reducing the depolarization-induced and ischemia-induced glutamate release. There are 
two major subtypes of GABA receptors, including the anion channels GABAA and presynaptic 
G-protein coupled receptors GABAB. In both in vivo and in vitro animal stroke models, 
sciencists have shown that elevation of extracellular GABA levels leads to reduction of 
GABAA receptor density (Hiu et al. 2016; Schwartz-Bloom and Sah 2001). In multiple clinical 
trials, drugs based on GABAergic mechanisms have shown to be successful on protecting the 
brain in several neurologic diseases, such as anxiety disorders, depression, seizures, 
Parkinson’s disease and Alzheimer’s disease (Greenfield 2013; Jo et al. 2014; Luscher, Fuchs, 
and Kilpatrick 2011; Rudolph and Möhler 2014; Vithlani et al. 2011). 
 
1.4 Therapeutic targets for ischemic stroke 
 
1.4.1a AMPA receptors 
The application of AMPAR antagonists in potential stroke treatments are divided into two 
classes: competitive agents and non-competitive agents. On the one hand, NBQX and 6-cyano-
7-nitroquinoxaline-2,3-dione (CNQX) are widely used competitive agents for blocking 
AMPARs. GYKI 52466, on the other hand, serves as a commonly applied non-competitive 
agent. However, several reports in the literature highlight the controversial results on the 
neuroprotective effects of selective AMPA receptor antagonists (Nayak and Kerr 2013; 
Schauwecker 2010; Schielke et al. 1999). Brickley’s lab discovered that CNQX could increase 
GABA transmission in the cerebellum, indicating these agents might affect synaptic 
transmission by a non-AMPA mechanism(Brickley et al. 2001). Although NBQX has shown 
protective effects in reducing neuronal cell death in the hippocampal region, it has been 
suggested that treatment with NBQX was ineffective in reducing neurodegeneration in rat 
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stroke models (Meden et al. 1993). Since NBQX has a very short half-life (Ikonomidou et al. 
1996) when applied at relatively high dose in order to provide neuroprotection and it has a low 
solublity in water, therefore, it is not ideal for administration in human patients. Some studies 
on rat stroke model suggested that GYKI 52466 was effective in neuroprotection; however, the 
drug delivery to patients is complicate and it has side effects including hypothermia (Nayak 
and Kerr 2013). 
 
1.4.1b Ca2+-permeable AMPARs 
Studies have suggested that high ischemic susceptibility corresponds to increased Ca2+-
permeable AMPAR numbers, indicating that GluA2-lacking AMPARs are associated with 
hypoxia induced neuronal damage (Talos et al. 2006). In rat hippocampus, pyramidal neurons 
in the CA1 region are specially vulnerable to ischemic injury. Evidences have been provided 
showing that increased numbers of Ca2+-permeable AMPARs are related to delayed cell death 
in the rat hippocampal CA1 region (Anzai et al. 2003; Noh et al. 2005; Weiss 2011). In addition, 
neuronal injury was attenuated when Ca2+-permeable AMPAR blockers were applied after the 
ischemic insult has occurred (Noh et al. 2005). All in all, these results prompted our lab to 
further investigate Ca2+-permeable AMPARs as a therapeutic target for ischemic stroke. 
 
1.4.2 Perampanel 
Perampanel, also referred to by its trademarked name Fycompa, is a non-competitive AMPAR 
antagonist. The Food and Drug Administration (FDA) has approved Perampanel as the first 
orally active drug in patients with epilepsy for patients older than 12 (Rohracher et al. 2015). 
Similar to other AMPA receptor antagonists, preclinical studies of Perampanel have identified 
its broad-spectrum anti-seizure effects in acute seizure models (Frampton 2015; Patel 2015; 
Rogawski and Hanada 2013). However, apart from other AMPAR antagonists, Perampanel has 
a distinctively very long half-life in humans, with gradual accumulation in plasma that could 
contribute to the development of tolerance or desensitization-related effects. Since Perampanel 
is already FDA-approved for seizures, this encouraged our lab to further investigate if 
repurposing this drug for other neurological diseases, such as ischemic stroke, Alzheimer’s 
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disease and Parkinson’s disease, could provide an alternative neuroprotective therapy in 
preclinical animal studies. 
 
1.5 Adenosine signalling and LTP 
Adenosine signalling is also involved in synaptic plasticity, which associates with learning and 
memory. The level of LTP indicates how strong the synaptic strength is. Memory loss is 
considered to associated with impairment of LTP. There are two kinds of LTP, decaying LTP 
and non-decaying LTP, Dong’s lab suggested that restoration of AMPAR endocytosis can 
convert non-decaying LTP into decaying LTP (Dong et al. 2015). Since in the previous 
description, it has been demonstrated by our lab that adenosine A1 receptor is involved in 
AMPAR endocytosis. Moreover, both adenosine A1 and A2A receptors (A1Rs, A2ARs) have 
proved to be crucial to synaptic plasticity. A1R agonists such as CPA, attenuate LTP, whereas 
selective antagonists of A1Rs, such as DPCPX, facilitate LTP (De Mendonça and Ribeiro 2001). 
A potent A2AR agonist, 4-[2-[[6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-
yl]amino]ethyl]benzenepropanoic acid hydrochloride (CGS 21680), facilitated LTP in rat 
hippocampal slices (De Mendonça and Ribeiro 1994) while A2AR antagonist, 2-(2-Furanyl)-
7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH 58261), 
attenuated LTP (Almeida et al. 2003). These findings encourage us to further explore the 
relationship between adenosine signalling, AMPARs and LTP. 
 
1.6 Adenosine Receptors and LSP1 
Leukocyte-specific protein 1 (LSP1) is a small protein which is widely expressed in immune 
system, including monocytes, macrophages, neutrophils, and endothelium pre-B cells and B 
cells  (Le et al. 2015). LSP1 serves an important downstream substrate of p38 mitogen-
activated protein kinase (p38 MAPK) (Liu et al. 2005). In the Cayabyab Lab, we discovered 
that in rat hippocampal brain slices, A1R is associate with the activation of p38 MAPK, which 
further regulates GluA2-containing AMPAR endocytosis (Chen et al. 2014). These results 
provide a very intriguing clue regarding the possible novel role of LSP1 in A1R regulation on 
AMPARs and synaptic plasticity after stroke or hypoxia (see illustration below).  
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The following illustration depicts the major molecular players under investigation in this 
current study. In brief, we propose that during hypoxic insult to the brain, both of the major 
adenosine receptor subtypes in the hippocampus, namely the inhibitory A1Rs and stimulatory 
A2ARs, alter the expression levels and the properties of AMPARs (but not NMDARs) after 
the post-hypoxia reperfusion period. We suggest that novel molecular players in adenosinergic 
signalling, including the serine/threonine protein kinase CK2, the F-actin-binding protein LSP1, 
and the MAPKs (p38 and JNK), are important downstream targets of A1Rs during and after 
hypoxic insults. The current study provides a foundation for future investigations of these 
signalling pathways in hypoxic/ischemic brain damage. 
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2. Hypothesis and Objectives 
 
Overall Hypothesis: We hypothesize that hypoxia induces A1R-mediated, dynamin-dependent 
internalization of A1Rs and GluA2/GluA1 AMPARs, which is then followed by an A2AR-
mediated upregulation of these AMPARs, which is a prerequisite for full expression of APSP 
and increased neuronal damage. 
 
Overall Objectives: 
1. Using fEPSP recordings, I will determine the cellular and molecular basis for the adenosine-
mediated post-hypoxia synaptic potentiation (APSP), in conjunction with known AMPAR 
antagonists. 
 
2. I will determine whether there is a functional cross-talk between A1R and A2AR, and 
whether this contributes to neuronal damage after hypoxia. 
 
3. I will also determine the novel role of the protein LSP1 in the brain, and specifically provide 
early evidence of whether this protein contributes to A1R-mediated changes in synaptic 
plasticity. 
 
4. I will determine whether revisiting the potential for AMPAR antagonist as effective 
neuroprotective therapy with the advent of Perampanel, can provide the basis for further 
preclinical and clinical studies in stroke treatments. 
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3. Material and Methods 
 
3.1 Animal Subjects 
Animal care and all experimental procedures were performed by following the guidelines of 
the Canadian Council for Animal Care (CCAC) and were in line with the ARRIVE guidelines. 
Animal related experimental procedures are carried out under the supervision of Animal Care 
and Supply in the University of Saskatchewan Committee (Approved Animal Use Protocol 
Number: 20070090). Post-natal male Sprague-Dawley rats (20–30 days) were caged in groups 
of four. Housing temperature was maintained at 20 °C to 24 °C with a natural light (12 
hours)/dark (12 hours) cycle. Rats were purchased by staff at the Lab Animal Service Unit 
(LASU) from Charles River Canada in Montreal. LSP1-deficient mice (knockout [KO]) (12-
15 weeks) with wild type (WT) 129/SvJ background were generated and provided to Dr. Lixin 
Liu’s lab (collaborator, Department of Pharmacology, University of Saskatchewan) as gift from 
the University of Toronto. Animal protocols applied on the control group (WT, 129/SvJ) in this 
study were approved by the Animal Care and Supply committee at the University of 
Saskatchewan. All rats and mice used in this study had unlimited access to tap water and 
standard pelleted diet provided by staff at LASU. 
 
3.2 Preparation of Hippocampal Slices 
Sprague-Dawley rats (postnatal 20-30 days), WT mice (12-15weeks), LSP1-deficient KO mice 
(12-15 weeks) were anaesthetized with halothane before utilization. All rats used are 
male.Brains are acquired after rapidly decapitated of the animals and were immediately 
transferred and submerged in ice-cold and oxygenated (aerating with 95% O2 and 5% CO2) 
The recipe for high concentration sucrose dissection solution is described as following (in mM): 
87 NaCl, 7.0 MgCl2,1.25 NaH2PO4, 1.25 NaH2PO4, 25 glucose, 25 NaHCO3, 2.5 KCl and 0.5 
CaCl2 (CaCl2 was added after the solution being oxygenated) (Brust et al. 2007; Chen et al. 
2014). Fully automated vibrating blade microtome (VTS1200S, Leica Instruments, Germany) 
was used to obtain hippocampal slices at 400 µm thickness. Brain slicing were conducted in 
the same ice-cold and oxygenated high concentration sucrose solution described as above. 
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Hippocampal slices were incubated in the solution for more than 90 min before further 
experiments were performed at 20 °C to 24 °C in oxygenated artificial cerebrospinal fluid 
(aCSF). The recipe for aCSF is decribed as following (in mM): 2.5 KCl, 126 NaCl, 26 NaHCO3, 
2.0 MgCl2, 10 glucose 1.25 NaH2PO4 and 2.0 CaCl2 (CaCl2 was added after the solution being 
oxygenated) (Brust et al. 2007; Chen et al. 2014). 
 
3.3 Electrophysiology 
Continuous perfusion of oxygenated aCSF at 3 ml/min with different drug treatment in the 
electrophysiology recording chamber was started before performing electrical stimulation of 
hippocampal slices. A bipolar tungsten electrode was used for stimulating the Schaffer 
collateral pathway to evoke field excitatory postsynaptic potentials (fEPSPs) by orthodromic 
stimulation. Recordings of the fEPSP signals were performed by a glass microelectrode filled 
with aCSF which was placed in CA1 stratum radiatum. A high-resolution, low-noise digitizer 
Digidata® 1440A was used to digitize the fEPSP signals. Signals were analyzed using Axon™ 
pCLAMP® 9 Electrophysiology Data Acquisition & Analysis Software (Foster City, CA). 
During every experiment, the fEPSPs were evoked by 0.1ms stimulation for every 30 seconds. 
Before choosing the standard stimulation amplitude for fEPSPs signals, a maximum amplitude 
was evoked for every hippocampal slice after a 20-min perfusion period of aCSF. For long term 
potentiation studies, the stimulation amplitudes were reduced to around one third of the 
maximum amplitude. For other electrophysiology studies in this project, the stimulation 
amplitudes were reduced to around half of the maximum amplitude. Stimulation voltage were 
mildly adjusted in case that the baseline is unstable. Baseline recording was conducted for at 
least 10 min to ensure a stable baseline fEPSP recording. Hypoxia treatment described in the 
following experiments was accomplished by aerating the aCSF with the mixture of 95% N2 
and 5% CO2 for at least 20 minutes. Despite the fact that the recording chamber was open to 
air and the aerating solution was placed in an open container, oxygen in the solution was 
replaced by nitrogen, so the solution was considered hypoxic. For Chemically induced long-
term potentiation (cLTP) experiments, cLTP was achieved by the treatment of 10 min Forskolin 
(50 µM) and Rolipram (0.1 µM) in a Mg2+-free aCSF solution. After the induction of 10-min 
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cLTP, fEPSPs were recorded during a 60 minutes normoxic washout period in normal aCSF 
(Mg2+-containing). A 10min baseline was recorded for the stableness of the signal. fEPSP 
slopes were normalized based on the first 10 sweeps (i.e. 5 min) after the perfusion of each 
treatment started.  
 
3.4 Propidium Iodide Staining 
To indicate cell death in the rat hippocampus, propidium iodide (PI) was selected as a 
fluorescent marker due to its ability of entering cells with damaged plasma membranes 
(Pugliese et al. 2009). This commonly applied method was also recently described by our lab 
(Stockwell et al. 2016). For prior incubation experiments, after generating the rat hippocampal 
slices, I incubated the slices in the oxygenized aCSF solution containing the drug treatment for 
60 minutes. Slices were then transferred to hypoxic aCSF solution for 20 minutes, followed by 
a 3-hour oxygenized aCSF washout. For normal perfusion experiments, slices were treated the 
with drug perfused at certain time points, and then washout for 3 hours. In the third hour of the 
washout, Propidium iodide (PI, 5 μg/ml) was added to the oxygenized aCSF solution. After 
adding PI, slices were immediately covered with aluminum foil. From this time point, all 
related procedures were conducted in the dark to prevent photobleaching of PI. Slices were 
then transferred in 12-well plates, with maximum of three slices in each well. After rinsing with 
aCSF, 4% paraformaldehyde were added in each well to fix the slices overnight at 4°C. On the 
second day of the experiment, slices were washed in 1X PBS for 10 minutes and then repeated 
twice. Slices were then transferred and mounted on glass microscope slides (two slices on one 
slide) after adding Prolong Gold Antifade Reagent. Confocal microscope Zeiss LSM 700 (Carl 
Zeiss, Germany) were used to image the slices. PI fluorescence were induced by 543 laser 
(green). 10 X objective lens was used to image the whole hippocampal slice and Zeiss Plan-
Apochromat 63 X /1.4 oil objective lens (Carl Zeiss, Germany) was used to image the CA1 
region of the hippocampal slices. Background parameters were first determined by slices with 
the most observed fluorescence (treatment by hypoxia alone) and were applied in all other 
treatment groups. The images of the hippocampal CA1 region were captured using Z-stack. 
Each Z-stack image was captured at 2 µm with 200 µm depth into the slices. For densitometry 
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analysis, the average of two Z-stack image were captured for each slice. Zeiss Zen 2009 version 
5.5 software (Carl Zeiss, Germany) were used to perform image capture. Image data were 
analyzed by ImageJ. The top and bottom Z-stack images were not included in the analyze since 
neuronal damage in these regions were partially caused by slicing procedure. The final images 
were generated in Adobe Photoshop CC (Adobe Systems, OS X operating system) by 
assembling the captured image into the whole hippocampal slice. 
 
3.5 Biochemistry Studies 
Rat hippocampal brain slices generated by previously described procedures (Chen et al. 2014, 
2016; Stockwell et al. 2016) were washed three time in aCSF before transferred into 1 mg/ml 
NHS-SS-Biotin containing 4°C aCSF. After 45 minutes incubation, slices were then transferred 
into quenching buffer (192 mM glycine, 25 mM Tris, pH 8.3) to stop the reactions, followed 
by 10 minutes washing in aCSF for three times. Slices were then homogenized in lysis buffer 
(1 mM EDTA, 1 mM NaF, 50 mM Tris, 150 mM NaCl, 10 μg/μl aprotinin, 10 μg/ml leupeptin, 
10 μg/ml pepstatin A, 2 mM Na3VO4, 20 mM sodium pyrophosphate, 1 mM PMSF) with 1% 
NP-40 and centrifuged to obtain the supernatant. Bradford Assay were performed to determine 
the protein concentrations. 500 μg of the biotinylated protein lysates in each treatment were 
diluted in lysis buffer. Equal amount of streptavidin beads was added to the lysates before 
incubation overnight at 4°C. On the following day, beads were washed with lysis buffer 
containing 0.1% NP-40 for 4 times. Each protein sample was then boiled at 95°C for 5 minutes 
with 50 μl of 2 X Laemmli sample buffer. Samples were separated by running through 10% 
polyacrylamide gel and transferred to PVDF membranes for 3 hours at 0.4 A. Membranes were 
then blocked in 5% nonfat milk in TBST (137 mM NaCl, 2.7 mM KCl, 19 mM Tris base) for 
one hour and probed with GluA1, GluA2 and GAPDH primary antibodies in TBST with 5% 
nonfat milk and 0.025% sodium azide at 4°C overnight. On the following day, membranes were 
washed four time in TBST (15 minutes each) and incubated with appropriate mouse or rabbit 
secondary antibodies (1:1000) for one hour. After washing in TBST for four times (15 minutes 
each). Enhanced chemiluminescence (ECL) reagent (Bio-Rad) were applied on the membrane 
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to visualizing the proteins. Both molecular weight of the biotinylated lysates and whole cell 
lysates are determined based on following information: GluA1 (100 kDa), GluA2 (100 kDa) 
and GAPDH (37 kDa). 
 
3.6 Drug Treatments 
N6-cyclopentyladenosine (CPA) (Sigma) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) 
(Sigma) were selected as A1R agonist at 5 mg/kg and A1R antagonist at 5 mg/kg, respectively. 
The amino acide sequence of the Tat-GluA2-3Y (YG) (GL Biochem) peptide is described as 
following YGRKKRRQRRR-869YKEGYNVYG877 and the scrambled version: 
YGRKKRRQRRR-VYKYGGYNE. The function of YG and scrambled YG (GL Biochem) are 
described in previous studies. (Chen et al. 2015) CPA, DPCPX, YG peptide and scrambled YG 
were dissolved in DMSO (Sigma) before intraperitoneal injection (i.p. injection) were 
performed on animals. Bath applied drug in electrophysiology studies are describe as following: 
6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Tocris), potent AMPAR antagonist; 6,7-
Dinitroquinoxaline-2,3-dione (DNQX) (Tocris), non-NMDAR antagonist; 2,3-Dioxo-6-nitro-
1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) (Tocris), AMPAR antagonist; 
(5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine maleate (MK 
801) (Tocris), NMDAR antagonist; D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5) 
(Tocris), NMDAR antagonist; N-[3-[[4-[(3-Aminopropyl)amino]butyl]amino]propyl]-1-
naphthaleneacetamide trihydrochloride (NASPM) (Tocris), Ca2+-permeable AMPAR 
antagonist; (S)-N-[7-[(4-Aminobutyl)amino]heptyl]-4-hydroxy-α-[(1-
oxobutyl)amino]benzenepropanamide dihydrochloride (Philanthotoxin 74) (Tocris), GluA1- 
and GluA3-containing AMPAR antagonist; and N,N,H,-Trimethyl-5-[(tricyclo[3.3.1.13,7]dec-
1-ylmethyl)amino]-1-pentanaminiumbromide hydrobromide (IEM 1460) (Tocris), non-
GluA2-containing AMPARs. All bath applied drugs were dissolved in DMSO before adding to 
aCSF. In each treatment, the final concentration of DMSO is less than 0.1%. Dynasore hydrate, 
a GTPase dynamin inhibitor, was purchased at Sigma, and also dissolved in DMSO before 
applied to bath treatment. 
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3.7 Statistical Analysis 
PI staining densitometry are calculated with Quantity 1, made by Bio-Rad and a public domain 
software, ImageJ. For biochemical analysis, a one-way ANOVA and post hoc Student-
Newman-Keuls were performed in order to generate the significance of different treatment 
groups. For electrophysiology study analysis, Turkey-Kramer tests were performed on top of 
one-way ANOVA analysis. All statistical analysis was generated by GraphPad Prism InStat 
(Version 3.0) on the operating system of Windows 10. 
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4. Results 
 
4.1 Full expression of APSP is regulated by clathrin-mediated, dynamin-dependent 
internalization of GluA1- and GluA2-containing AMPARs 
 
Previously in our lab we have shown that prolonged A1R stimulation led to clathrin-mediated 
AMPA receptor endocytosis (Chen et al. 2014, 2016). We have also shown that during hypoxia, 
elevated extracellular adenosine in the hippocampus stimulates adenosine A1Rs and A2ARs 
and leads to adenosine-mediated post-hypoxia synaptic potentiation or APSP (Stockwell et al. 
2016). Additionally, by using imaging techniques, we confirmed that in the hippocampal 
neurons, functional A1Rs are required for clathrin-mediated AMPAR endocytosis. However, 
A2ARs are not involved in the AMPAR endocytosis process. (Chen et al. 2014). Since the 
application of A1R antagonist DPCPX inhibits the level of APSP, it is crucial to test whether 
the inhibitory effect on APSP by this A1R antagonist requires the clathrin-mediated endocytosis 
pathway. Therefore, I first performed experiments comparing the level of APSP in absence or 
presence of Dynasore, a drug which has been used by our lab and other laboratories to block 
dynamin-dependent endocytosis (Chen et al. 2016; Macia et al. 2006). As shown in Figure 4.1, 
hippocampal slices perfused with 50 µM Dynasore showed attenuated level of APSP when 
compared to slice perfused with normal aCSF (Figure. 4.1 A-D). Next, I performed PI staining 
experiments to show that pre-incubation with Dynasore prevented hypoxia-induced cell death 
in rat hippocampal CA1 region (Figure. 4.1. E, F). Thus, these results suggest that prior 
stimulation of functional A1Rs and subsequent A1R internalization (i.e., dynamin-dependent) 
are required for the full expression of APSP, through clathrin-mediated AMPA receptor 
endocytosis pathway in rat hippocampal brain slices. These results also suggest that dynamin-
dependent processes after hypoxia-induced adenosine receptor stimulation contribute to 
hippocampal neuronal damage. 
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Figure 4.1. 
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Figure 4.1.  Hypoxia (20 min) induced APSP and widespread neuronal death in acute 
hippocampal brain slices, as shown using propidium iodide (PI) staining. This 
neurodegeneration was attenuated by pre-incubation with the clathrin-mediated endocytosis 
inhibitor Dynasore. Slices pre-incubated with Dynasore also inhibited APSP levels after 20 min 
hypoxia treatment compared to control. A. Sample fEPSP traces. (1) showing the average trace 
of the last 5 minutes of the 10 minutes baseline. (2) showing the average trace of the last 5 
minutes of the 20 minutes hypoxia treatment. (3) showing the average trace of the last 5 minutes 
of 45 minutes washout period. (1 + 2 + 3) showing the overlay of the three traces. B. Sample 
fEPSP traces. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. 
(2) showing the average trace of the last 5 minutes of the 20 minutes hypoxia treatment. (3) 
showing the average trace of the last 5 minutes of 45 minutes washout period. (1 + 2 + 3) 
showing the overlay of the three traces. 50 µM Dynasore was perfused from the start of baseline. 
C. Summary time course plot showing mean fEPSP values with or without 50 µM Dynasore 
perfusion normalized to baseline (100%) D. Summary bar graph showing mean fEPSP values 
at the end of the normoxic washout period.  Means ± SEM. Significance: * p < 0.05. N = 8 
recordings per group. E. Representative images of hippocampal slices (large panels) stained 
with PI. Area CA1 (small panel, top right of each panel) was analyzed to compare relative PI 
intensity. Scale bars: 1mm (large panel) and 10 µm (small panel) apply to all confocal images 
F. Bar graph showing relative PI intensity in area CA1. Scale bars, 10 ms, 0.5 mV. Mean 
fluorescence intensities ± SEM are shown. Significance: * p <0.05. N = 6 independent 
experiments.  
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4.2 Synaptic transmission in rat hippocampal CA1 region is mainly mediated by AMPA-
ergic mechanisms, instead of NMDA receptors 
 
Previously, our lab showed that stimulation of adenosine A1Rs leads to GluA2 and GluA1 
AMPAR internalization via clathrin-mediated and dynamin-dependent endocytosis (Chen et al. 
2014). Thus, we hypothesized that AMPA-ergic receptors are mainly involved in mediating 
synaptic transmission in rat hippocampus. First, I perfused a potent AMAPAR antagonist, 
CNQX, which significantly decreased field EPSP levels in rat hippocampal brain slice 
recordings (Figure. 4.2-1 A, B). DNQX (Figure. 4.2-1 C, D), a selective non-NMDA receptor 
antagonist, showed the similar result. I also tested NBQX, a potent, selective and competitive 
AMPA receptor antagonist (Figure. 4.2-1 E, F), which had significant blocking effect on the 
EPSP. These AMPAR antagonists abolished around 95% of fEPSPs after 30 min of drug 
applications (Figure. 4.2-1 G). In previous studies, the excitotoxicity during the process of 
ischemic stroke is also shown to be mediated by NMDA receptors. Therefore, we also tested if 
NMDAR antagonists show similar effect as the AMPA-ergic receptor blockers. After applying 
D-AP5, a competitive NMDA antagonist (Figure.4.2-2 A, B), I did not observe any significant 
change in the amplitudes of field EPSP recordings, and similar results were shown with the 
application of MK-801, a potent non-competitive NMDA receptor antagonist (Figure. 4.2-2 C, 
D, summarized in Figure. 4.2-2 E). In fact, I observed a moderate (but non-significant) increase 
in synaptic transmission after MK-801 treatments. We concluded that the synaptic transmission 
in rat hippocampal CA1 region is mostly mediated by AMPA-ergic receptors, instead of NMDA 
receptors. 
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Figure 4.2-1. 
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Figure 4.2-1.  fEPSP levels were significantly blocked by AMPA-ergic antagonists CNQX, 
DNQX and NBQX. A. Summary time course plot showing mean fEPSP after application of 
CNQX (10 µM). B. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes 
of the 10 minutes baseline. (2) showing the average trace of the last 5 minutes of the 30 minutes 
CNQX treatment. (1 + 2) showing the overlay of the two traces. C. Summary time course plot 
showing mean fEPSP after application of DNQX (10 µM). D. Sample fEPSP traces. (1) 
showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) showing the 
average trace of the last 5 minutes of the 30 minutes DNQX treatment. (1 + 2) showing the 
overlay of the two traces. E. Summary time course plot showing mean fEPSP after application 
of NBQX (10 µM). F. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes 
of the 10 minutes baseline. (2) showing the average trace of the last 5 minutes of the 30 minutes 
NBQX treatment. (1 + 2) showing the overlay of the two traces. G. Summary bar graph 
showing mean fEPSP values after application of CNQX (10 µM), DNQX (10 µM) and NBQX 
(10 µM). Scale bars, 10 ms, 0.5 mV. Means ± SEM. Significance: *** p < 0.005. N = 7 
recordings per group. 
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Figure 4.2-2. 
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Figure 4.2-2.  No significant changes were shown for fEPSP levels after applying NMDAR 
antagonists D-AP5 and MK-801. A. Summary time course plot showing mean fEPSP after 
application of D-AP5 (100 µM). B. Sample fEPSP traces. (1) showing the average trace of the 
last 5 minutes of the 10 minutes baseline. (2) showing the average trace of the last 5 minutes 
of the 30 minutes D-AP5 treatment. (1 + 2) showing the overlay of the two traces. C. Summary 
time course plot showing mean fEPSP after application of MK-801 (5 µM). D. Sample fEPSP 
traces. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) 
showing the average trace of the last 5 minutes of the 30 minutes MK-801 treatment. (1 + 2) 
showing the overlay of the two traces. E. Summary bar graph showing mean fEPSP values after 
application of MK-801 (5 µM) and D-AP5 (100 µM). Scale bars, 10 ms, 0.5 mV. Means ± 
SEM. Significance: NS p > 0.05. N = 7 recordings per group. 
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4.3 Adenosine induced post-hypoxia synaptic potentiation is also meditated by AMPA-
ergic receptors instead of NMDA receptors.  
 
We predicted that changes in synaptic transmission levels (i.e., enhanced fEPSPs) during the 
post-hypoxia period would be accompanied by increased neuronal susceptibility and may 
indicate delayed neuronal damage occurring after normoxic reperfusion of the rat hippocampal 
slices. In order to investigate which kind of glutamate receptors are regulating this process, I 
tested whether AMPA-ergic receptors are involved in the post-hypoxia synaptic potentiation 
that we normally observed during normoxic reperfusion. Surprisingly, the AMPAR antagonists 
CNQX, DNQX and NBQX abolished all the fEPSPs instead of merely decreasing the fEPSP 
levels back to baseline (Figure. 4.3-1 A-F, summarized in G). We initially hypothesized that 
the APSPs were mediated by enhanced NMDAR function. Therefore, we were also surprised 
that the tested NMDAR antagonists failed to show a similar effect as the AMPAR antagonists 
in abolishing the APSPs. Instead, when I perfused either MK-801 or D-AP5 following the 45 
min reperfusion, I observed a moderate, but not significant, enhancement of fEPSPs in the rat 
hippocampal CA1 region (Figure. 4.3-2 A-D, summarized in E). Together, the results suggest 
that the APSP is mainly mediated by AMPAR-related mechanisms likely involving the A1R 
activation pathway. 
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Figure 4.3-1. 
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Figure 4.3-1.  fEPSP levels after post-hypoxia reperfusion were significantly blocked by 
AMPA-ergic antagonists CNQX, DNQX and NBQX. A. Summary time course plot showing 
mean fEPSP after application of CNQX (10 µM). B. Sample fEPSP traces. (1) showing the 
average trace of the last 5 minutes of the 10 minutes baseline. (2) showing the average trace of 
the last 5 minutes of the 20 minutes hypoxia treatment. (3) showing the average trace of the 
last 5 minutes of 45 minutes washout period. (4) showing the average trace of the last 5 minutes 
of the 30 minutes CNQX treatment. (1 + 2 + 3 + 4) showing the overlay of the four traces. C. 
Summary time course plot showing mean fEPSP after application of DNQX (10 µM). D. 
Sample fEPSP traces. (1) showing the average trace of the last 5 minutes of the 10 minutes 
baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes hypoxia 
treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout period. 
(4) showing the average trace of the last 5 minutes of the 30 minutes DNQX treatment. (1 + 2 
+ 3 + 4) showing the overlay of the four traces. E. Summary time course plot showing mean 
fEPSP after application of NBQX (10 µM). F. Sample fEPSP traces. (1) showing the average 
trace of the last 5 minutes of the 10 minutes baseline. (2) showing the average trace of the last 
5 minutes of the 20 minutes hypoxia treatment. (3) showing the average trace of the last 5 
minutes of 45 minutes washout period. (4) showing the average trace of the last 5 minutes of 
the 30 minutes NBQX treatment. (1 + 2 + 3 + 4) showing the overlay of the four traces. G. 
Summary bar graph showing mean fEPSP values after application of CNQX (10 µM), DNQX 
(10 µM) and NBQX (10 µM). Scale bars, 10 ms, 0.5 mV. Means ± SEM. Significance: *** p 
< 0.005. N = 7 recordings per group. 
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Figure 4.3-2. 
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Figure 4.3-2.  No significant change was observed for fEPSP levels during post-hypoxia 
period after applying NMDAR antagonists MK-801 and D-AP5. A. Summary time course plot 
showing mean fEPSP after application of MK-801 (5 µM). B. Sample fEPSP traces. (1) 
showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) showing the 
average trace of the last 5 minutes of the 20 minutes hypoxia treatment. (3) showing the average 
trace of the last 5 minutes of 45 minutes washout period. (4) showing the average trace of the 
last 5 minutes of the 30 minutes MK-801 treatment. (1 + 2 + 3 + 4) showing the overlay of the 
four traces. C. Summary time course plot showing mean fEPSP after application of D-AP5 
(100 µM). D. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes of the 
10 minutes baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes 
hypoxia treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout 
period. (4) showing the average trace of the last 5 minutes of the 30 minutes D-AP5 treatment. 
(1 + 2 + 3 + 4) showing the overlay of the four traces. E. Summary bar graph showing mean 
fEPSP values after application of MK-801 (5 µM) and D-AP5 (100 µM). Scale bars, 10 ms, 
0.5 mV. Means ± SEM. Significance: NS p > 0.05. N = 7 recordings per group. 
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4.4 Ca2+-permeable AMPAR blockers inhibited post-hypoxia synaptic transmission when 
applied early during hypoxia insult, but had no significant effect when applied after post-
hypoxia reperfusion 
 
Since the post-hypoxia synaptic transmission was mostly mediated by an AMPA-ergic 
mechanism, I decided to test which type of AMPARs are involved in contributing to the APSP. 
I perfused Philanthotoxin-74, a selective inhibitor of Ca2+-permeable AMPARs after APSP 
during CA1 recordings. Surprisingly, this antagonist did not modify the fEPSPs when applied 
45 min after initiating the normoxia reperfusion (Figure. 4.4-1 A, B). Similar results were 
observed with either NASPM (Figure. 4.4-1 C, D), another Ca2+-permeable AMPAR antagonist, 
or IEM 1460 (Figure. 4.4-1 E, F), a more selective antagonist for GluA2 subunit-lacking 
receptors over GluA2-containing receptors. Previous reports (Chen et al. 2014; Stockwell et al. 
2016) suggested that chronic A1R stimulation leads to desensitization of A1Rs, which is then 
followed by increased insertion of A2ARs during ischemic conditions. It was also suggested 
that during hypoxic periods, both GluA1 and GluA2 surface levels remained depressed but that 
the GluA1 levels quickly recover upon normoxic reperfusion while GluA2 remained depressed 
(Stockwell et al. 2016). This led to the hypothesis that the A2AR stimulation by endogenous 
adenosine during normoxic reperfusion could induce rapid and transient insertion of calcium-
permeable GluA1-containing AMPARs. Unpublished observations from our lab confirmed that 
pre-incubation with either DPCPX or SCH 58621 (A1R and A2AR antagonist, respectively) 
prevented the appearance of APSPs, which suggests a strong cross-talk between A1Rs and 
A2ARs. Therefore, we hypothesized that a transient insertion of GluA1-containing AMPARs 
during the early phase of normoxic reperfusion could contribute to the adenosine receptor 
dependent post-hypoxia synaptic potentiation. Thus, I tested whether early application of these 
same calcium-permeable AMPAR antagonists will show an inhibitory effect on the APSP levels. 
When drugs were applied after 5 min of hypoxia treatment until the end of the washout period, 
I did observe a decreased level of APSP after 45 min of reperfusion. (Figure. 4.4-2 A-D, 
summarized in E). These results suggested that delayed administration of Ca2+-permeable 
AMPA receptor blockers have little neuroprotective effect on rat hippocampal slices whereas 
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application around the time of insult could attenuate the function of GluA1-containing 
AMPARs and decrease APSP levels and neuronal damage. 
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Figure 4.4-1. 
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Figure 4.4-1.  No significant change was observed in fEPSPs when Ca2+-permeable AMPAR 
antagonists were applied 45 min after initiating the normoxia reperfusion. A. Summary time 
course plot showing the effect of Philanthotoxin-74 (50 µM) on fEPSPs when applied after 45 
min of reperfusion. B. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes 
of the 10 minutes baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes 
hypoxia treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout 
period. (4) showing the average trace of the last 5 minutes of the 30 minutes Philanthotoxin-74 
treatment. (1 + 2 + 3 + 4) showing the overlay of the four traces. C. Summary time course plot 
showing mean fEPSPs and the effect of applying NASPM (50 µM) 45 min after reperfusion. 
D. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes of the 10 minutes 
baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes hypoxia 
treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout period. 
(4) showing the average trace of the last 5 minutes of the 30 minutes NASPM treatment. (1 + 
2 + 3 + 4) showing the overlay of the four traces. E. Summary time course plot showing mean 
fEPSPs and the effect of IEM 1460 (50 µM) after 45 min of reperfusion. F. Sample fEPSP 
traces. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) 
showing the average trace of the last 5 minutes of the 20 minutes hypoxia treatment. (3) 
showing the average trace of the last 5 minutes of 45 minutes washout period. (4) showing the 
average trace of the last 5 minutes of the 30 minutes IEM 1460 treatment. (1 + 2 + 3 + 4) 
showing the overlay of the four traces. G. Bar graph showing the lack of effect of 
Philanthotoxin-74 (50 µM), NASPM (50 µM) and IEM 1460 (50 µM) on APSPs when these 
drugs were applied 45 min after initiating normoxic reperfusion. Scale bars, 10 ms, 0.5 mV. 
Means ± SEM. Significance: NS p > 0.05. N = 7 recordings per group.  
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Figure 4.4-2. 
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Figure 4.4-2.  fEPSP levels after post-hypoxia reperfusion were attenuated when Ca2+-
permeable AMPAR inhibitors were applied after 5 min of hypoxia treatment. A. Summary time 
course plot showing mean fEPSPs and the effect of applying IEM 1460 (50 µM) soon after 
hypoxia treatment (i.e., 5min of start of hypoxia) and throughout normoxic reperfusion washout 
period. B. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes of the 10 
minutes baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes hypoxia 
treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout period. (1 
+ 2 + 3) showing the overlay of the three traces. IEM 1460 treatment was started from 5 min 
of hypoxia till the end of washout. C. Summary time course plot showing similar effect of 
Philanthotoxin-74 (50 µM) as IEM 1460 in inhibiting the APSPs when applied immediately 
after hypoxia treatment (i.e., 5 min of hypoxia onset) and throughout the normoxia reperfusion 
washout period. D. Sample fEPSP traces. (1) showing the average trace of the last 5 minutes 
of the 10 minutes baseline. (2) showing the average trace of the last 5 minutes of the 20 minutes 
hypoxia treatment. (3) showing the average trace of the last 5 minutes of 45 minutes washout 
period. (1 + 2 + 3) showing the overlay of the three traces. Philanthotoxin-74 treatment was 
started from 5 min of hypoxia till the end of washout. E. Summary bar graph showing mean 
fEPSP values of APSP and the inhibitory effects of IEM 1460 (50 µM) and Philanthotoxin-74 
(50 µM) when applied 5 min after onset of hypoxia and lasting throughout the normoxia 
reperfusion washout period. Scale bars, 10 ms, 0.5 mV. Means ± SEM. Significance: * p < 
0.05. N = 7 recordings per group.  
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4.5 Early blockade of Ca2+-permeable AMPARs prevents neuronal damage induced by 
hypoxia in rat hippocampus 
 
To further confirm my results on Ca2+-permeable AMPAR blockers from above 
electrophysiological experiments, I performed propidium iodide (PI) staining experiments to 
compare levels of cell damage when Ca2+-permeable AMPAR blockers were applied at 
different time points. Early application (5 min into hypoxia till the end of washout) of IEM 
1460, Philanthotoxin-74 and NASPM in rat hippocampal slices both dramatically reduced cell 
damage compared to much later application of the drugs (i.e., 45 min of reperfusion) which 
produced no protection of hippocampal neurons (Figure. 4.5 A-C, summarized in D). These 
results showed that the adenosine-induced post-hypoxia synaptic potentiation (APSP) 
accompanying neuronal damage that we observed was likely due, in part, to increased function 
and transient insertion of CP-AMPARs. This novel mechanism may provide further insight into 
the possible reasons for failure of glutamate receptor blockers in clinical trials involving 
patients suffering from stroke. 
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Figure 4.5. 
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Figure 4.5.  Hypoxia (20 min) induced widespread neuronal death in acute hippocampal 
slices, as shown using propidium iodide (PI) staining. This neuronal death was prevented with 
early application of Philanthotoxin-74 (50 µM), IEM 1460 (50 µM) or NASPM (50 µM) 
starting at 5 min into the hypoxic insult (early), but not with application of the blockers after 
the washout (late, 45 min after start of normoxic washout). A. Representative images of 
hippocampal slices (large panels) treated with hypoxia, hypoxia with early application of 
Philanthitoxin-74 (50 µM) and hypoxia with late application of Philanthitoxin-74, treated with 
PI. Area CA1 (small panel, top right of each panel) was analyzed to compare relative PI 
intensity. B. Representative images of hippocampal slices (large panels) treated with hypoxia, 
hypoxia with early application of IEM 1460 (50 µM) and hypoxia with late application of IEM 
1460, treated with PI. Area CA1 (small panel, top right of each panel) was analyzed to compare 
relative PI intensity. C. Representative images of hippocampal slices (large panels) treated with 
hypoxia, hypoxia with early application of NASPM (50 µM) and hypoxia with late application 
of NASPM, treated with PI. Area CA1 (small panel, top right of each panel) was analyzed to 
compare relative PI intensity. D. Bar graphs showing relative PI intensity in area CA1. Mean 
fluorescence intensities ± SEM are shown. Significance: * p <0.05. N = 6 independent 
experiments. Scale bars: 1mm (large panel) and 10 µm (small panel) apply to all confocal 
images. 
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4.6 Perampanel attenuated post-hypoxia synaptic transmission and reduced neuronal 
damage  
 
Since Perampanel is also a non-competitive AMPAR antagonist and it is currently clinically 
approved for so called “drug-resistant” epileptic patients (age≥12 years old), it is intriguing 
for me to investigate whether Perampanel has neuroprotective effects on rat hippocampal slices 
after hypoxic insult. Surprisingly, unlike the other CP-AMPAR blockers I previously tested, 
administration of Perampanel (200 nM) after the 45 min normoxic washout did not abolish the 
baseline synaptic transmission but did attenuate the level of APSPs back to baseline (Figure 
4.6 A-B, summarized in C). These results suggested that Perampanel might represent a 
promising therapeutic agent to combat the delayed damaging effects of ischemia-reperfusion 
injury in stroke patients. However, the difference in the mechanism of action between 
Perampanel and other competitive AMPAR blockers still needs to be specified through further 
experiments. It is likely that Perampanel, in addition to having inhibitory effects on AMPARs, 
may have other off-target effects, such as a possible allosteric interaction with the GABAA 
receptor (GABAAR) and thereby increasing the GABAAR-mediated synaptic transmission in 
the hippocampus. The combined inhibitory effects on AMPAR/kainate receptor and 
stimulatory effects on GABAA receptor-mediated currents by the action of Perampanel may 
underlie the reduction in APSP during normoxic reperfusion (Figure 4.6 C) and reduction in 
hippocampal neuronal damage (Figure. 4.6 D, E), which is a mechanism that was suggested 
for the possible allosteric interaction of CNQX and subsequent increase in inhibitory synaptic 
transmission in the cerebellum (Brickley et al. 2001). Although this potentially novel dual 
effects of Perampanel on AMPARs (inhibitory) and GABAARs (stimulatory) could be 
important to explain both the reduced levels of APSPs and neuronal damage during post-
hypoxia normoxic washout, this is beyond the scope of my current studies but warrants further 
investigation in the future. 
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Figure 4.6. 
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Figure 4.6.  The fEPSP levels after post-hypoxia reperfusion were attenuated by Perampanel 
when applied after 45 min of reperfusion and Perampanel reduced neuronal death after post-
hypoxia reperfusion. A. Summary time course plot showing the inhibitory effects of 
Perampanel (200 nM) on APSPs when applied 45 min after reperfusion. B. Sample fEPSP 
traces. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) 
showing the average trace of the last 5 minutes of the 20 minutes hypoxia treatment. (3) 
showing the average trace of the last 5 minutes of 45 minutes washout period. (4) showing the 
average trace of the last 5 minutes of the 30 minutes Perampanel treatment. (1 + 2 + 3 + 4) 
showing the overlay of the four traces. C. Summary bar graph showing mean fEPSP values of 
APSP after application of Perampanel (200 nM). Means ± SEM. Significance: * p < 0.05. N = 
8 recordings per group. D. Representative images of hippocampal slices (large panels) treated 
with hypoxia, and hypoxia with application of Perampanel (1 μM), treated with PI. Area CA1 
(small panel, top right of each panel) was analyzed to compare relative PI intensity. D. Bar 
graphs showing relative PI intensity in area CA1. Scale bars, 10 ms, 0.5 mV. Mean 
fluorescence intensities ± SEM are shown. Significance: * p <0.05. N = 4 independent 
experiments. Scale bars: 1mm (large panel) and 10 µm (small panel) apply to all confocal 
images.  
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4.7 Long term potentiation (LTP) deficits after chronic A1R signalling 
 
Previously in our lab, we have shown that prolonged stimulation of A1R leads to A1R-induced 
persistent synaptic depression (APSD). Also, activation of adenosine A1R leads to GluA2 and 
GluA1 AMPAR internalization (Chen et al. 2014). Studies in other labs have shown that 
inhibiting endocytosis of postsynaptic AMPARs prevents LTP decay, which could lead to 
converting of LTP decay into nondecaying LTP (Dong et al. 2015). Moreover, inhibition of 
AMPAR endocytosis in rat model of Alzheimer’s disease improves memory and other 
cognitive functions (Dong et al. 2015). Thus, I decided to find out if the LTP deficits we 
observed involve adenosine A1R signalling through AMPARs. Rats were divided into three 
groups: Group A: Control group with DMSO intraperitoneal injection (i.p. injection) twice in 
48 hours. Group B: CPA group with A1R agonist CPA (5 mg/kg) i.p. injection twice in 48 hours. 
Group C: DPCPX group with CPA (5 mg/kg) and A1R antagonist DPCPX (5 mg/kg) i.p. 
injection twice in 48 hours (20 min prior to CPA i.p. injections). Acute hippocampal slices were 
acquired from three different treatment groups on the following day after the two-day injection 
for electrophysiological analysis on their effect on LTP. Rats in CPA group showed significant 
LTP deficits when compared to the control group, whereas the rats in the DPCPX + CPA group 
had similar levels of LTP as the control group (Figure 4.7 A-C, summarized in D). These results 
suggested that chronic or longer-term adenosine A1R signalling is involved in inducing LTP 
deficits. In other words, persistent A1R activation could induce AMPAR internalization (Chen 
et al. 2014), which could underlie the observed impairment of LTP that can then be countered 
by co-administering the A1R antagonist DPCPX. 
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Figure 4.7. 
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Figure 4.7.  LTP levels in rat hippocampus were decreased after CPA-induced A1R activation, 
which can be prevented by pretreatment with A1R antagonist DPCPX. A. Sample fEPSP traces 
for the DMSO group. (1) showing the average trace of the last 5 minutes of the 10 minutes 
baseline. (2) showing the average trace of the last 5 minutes of the 60 minutes cLTP washout. 
(1 + 2) showing the overlay of the two traces. B. Sample fEPSP traces for the CPA group. (1) 
showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) showing the 
average trace of the last 5 minutes of the 60 minutes cLTP washout. (1 + 2) showing the overlay 
of the two traces. C. Sample fEPSP traces for the DPCPX + CPA group. (1) showing the 
average trace of the last 5 minutes of the 10 minutes baseline. (2) showing the average trace of 
the last 5 minutes of the 60 minutes cLTP washout. (1 + 2) showing the overlay of the two 
traces. D. Summary time course plot showing mean fEPSP in three rat groups. Duration of 
chemical induction (with Rolipram and Forskolin) of LTP (cLTP) is denoted by the shaded 
region (total 10 min). E. Summary bar graph showing mean fEPSP values of three rat groups 
after washout of cLTP. Scale bars, 10 ms, 0.5 mV. Scale bars, 10 ms, 0.5 mV. Means ± SEM. 
Significance: ** p < 0.01, NS p > 0.05. N = 12 recordings per group.  
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4.8 LSP-1 knockout mice showed LTP deficits when compared to wild type mice  
 
Studies have indicated that adenosine is having pro-inflammatory effects by A1R signalling. 
Meanwhile, it also have anti-inflammatory effects through A2AR signalling (Nakav et al. 2008). 
Adenosine A1R is believed to regulate GluA2-containing AMPAR endocytosis through 
activation of p38 mitogen-activated protein kinase (p38 MAPK) (Chen et al. 2014). 
Interestingly, LSP1 is also known to serve as an important downstream substrate of p38 MAPK 
(Liu et al. 2005). Since A1R activation is involved in LTP impairment in rats, I aimed to provide 
a pilot study to establish a potential link between LSP1, adenosine A1R signalling, AMPARs 
and LTP induction and regulation. Our general hypothesis is that LSP1 may regulate 
endocytosis rates, and therefore, LSP1 knockout may increase the endocytosis of A1Rs and 
other receptors (Walther et al. 2006). My initial experiments aimed to investigate whether LSP1 
knockout mice have LTP deficits, which is consistent with an enhanced endocytosis rate when 
LSP1 is absent (Walther et al. 2006).  cLTP was induced in both LSP1 knockout mice and 
wild type mice. No significant difference was observed at the end of 10 min cLTP period, 
whereas I observed significant LTP deficit during the maintenance phase of LTP in LSP1 
knockout mice (i.e., at the end of one-hour washout period) (Figure. 4.8 C). These results 
suggested that LSP1 is involved in the generation of LTP, however, further experiments still 
need to be conducted to find out whether LSP1 is normally involved in regulating A1R and 
AMPAR surface localization and synaptic plasticity in LSP1 knockout mice. 
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Figure 4.8. 
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Figure 4.8.  LTP levels in mouse hippocampus were decreased after the one-hour LTP 
washout in LSP1 knockout mice compared to wild type mice, whereas no significant difference 
was observed at the end of cLTP perfusion period. A. Sample fEPSP traces for the wild type 
mice group. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) 
showing the average trace of the last 5 minutes of the 60 minutes cLTP washout. (1 + 2) 
showing the overlay of the two traces. B. Sample fEPSP traces for the LSP1 knockout mice 
group. (1) showing the average trace of the last 5 minutes of the 10 minutes baseline. (2) 
showing the average trace of the last 5 minutes of the 60 minutes cLTP washout. (1 + 2) 
showing the overlay of the two traces. C. Summary time course plot showing mean fEPSP in 
the two mouse groups. Note the biphasic response in the wild type mice, which is not observed 
in the LSP1 knockout mice. D. Summary bar graph showing mean fEPSP values of the two 
mouse groups at the end of cLTP perfusion period (10 min). E. Summary bar graph showing 
mean fEPSP values of the two mouse groups after the one-hour washout period after cLTP 
induction. Scale bars, 10 ms, 0.5 mV. Means ± SEM. Significance: ** p < 0.01. N = 12 
recordings per group. 
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4.9 Short-term treatment of CPA decreased surface expression of GluA2, while prolonged 
treatment with CPA increased GluA2 surface expression 
 
Since AMPAR trafficking is crucial in the process of neuron excitation, our lab has investigated 
whether A1Rs can functionally modify GluA2 and GluA1 AMPAR surface distribution in vitro 
and in vivo. Previously, we have shown that activation of A1Rs with CPA led to a significant 
reduction of GluA2 and GluA1 surface expression in hippocampal cultured neurons, which can 
be attenuated by DPCPX and “YG” peptide.  That is, when this YG peptide is fused with Tat-
domain peptide (which makes “YG” peptide become cell permeable), it allows selective 
inhibition of GluA2 clathrin-mediated endocytosis (Chen et al. 2014). In order to determine 
whether a similar inhibitory effect can be observed in vivo, I performed intraperitoneal (i.p.) 
injection of CPA with or without either DPCPX or YG peptide in adult rats. Following the 30-
minute i.p. injections, rats were sacrificed, and hippocampal slices were subsequently 
immediately processed for biotinylation to detect the surface localization of GluA2 in these 
hippocampal slices. Results in Figure 4.9 A are consistent with our results in in vitro studies 
(Chen et al. 2014). To further determine the effect of A1R stimulation in chronic conditions, I 
performed another long-term experiment, in which I injected rats twice with the same 
treatments as I did in the 30 min groups in two consecutive days (48 hours treatment). 
Surprisingly, an increased GluA2 surface expression was observed, which highlights the 
difference between acute vs. chronic effects of A1R signalling in regulating synaptic plasticity-
related molecular players. Future studies are needed to test whether the chronic A1R 
stimulation (as in the case of CPA i.p. injections for 2 consecutive days) results in an A1R-
A2AR cross-talk that ultimately results in increased desensitization of A1R and a subsequent 
increased surface expression of A2ARs. Based on the preceding results presented so far, I 
predict that this chronic A1R stimulation will result in A2AR-mediated increase in 
GluA1/GluA2 surface insertion due to increased A2AR-mediated post-translational 
modification of either or both AMPAR subunits, most likely via increased phosphorylation at 
serine or threonine residues. Further studies are needed to test this hypothesis, and to further 
identify the downstream A1R signalling pathways that are important in contributing to these 
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changes in GluA2/GluA1, A2AR and A1R in the early (acute) and late (chronic) phase of A1R 
stimulation that occurs in hypoxic/ischemic brain insults. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
Figure 4.9. 
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Figure 4.9. After injecting CPA (5 mg/kg) for 30 minutes, surface expression of GluA2 was 
downregulated when compared to the control group (i.e. injected with DMSO). This 
downregulation of GluA2 was attenuated by prior injection of DPCPX (5 mg/kg). Since the 
Tat-GluA2–3Y peptide particularly blocks clathrin-mediated GluA2 endocytosis, rats injected 
with CPA and YG peptide also showed similar results with the DPCPX group, whereas the 
scrambled YG peptide showed little effect on the reduction of GluA2 surface expression 
induced by CPA. However, in the 48-hour treatment group, CPA increased GluA2 surface 
expression. A. Western Blot data showing the different surface expression level of GluA2 after 
the acute treatment. A significant reduction of GluA2 surface expression was observed with 
CPA 30 minutes prior injection group when compared to control. Both injection of DPCPX and 
YG peptide attenuated the decrease of GluA2 surface expression, when no significant change 
was shown in the scrambled YG injected group when compared to the CPA injected group. B. 
Bar charts showing the level of biotinylated GluA2 in different treatment group after 
normalizing on the respective whole hippocampal slice cell lysates. C. Western Blot data 
showing the different surface expression level of GluA2 after the chronic treatment. A 
significant increase of GluA2 surface expression was observed with CPA 48 hours injection 
group when compared to control. Both injection of DPCPX and YG peptide attenuated the 
increase of GluA2 surface expression, when no significant reduction was shown in the 
scrambled YG injected group. Means ± SEM. Significance: * p < 0.05. N = 4 from four 
independent experiments 
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5. Discussion 
 
5.1 Adenosine A1 and A2A receptor cross-talk 
Previous studies in our lab (Stockwell and Cayabyab, unpublished) have demonstrated that 
blocking A1R or A2AR alone can reduce the adenosine-induced post-hypoxia synaptic 
potentiation (APSP), which strongly suggested a potential cross-talk between A1R and A2AR 
that could contribute to enhanced APSP levels and the associated neuronal damage after 
hypoxia treatments in the rat hippocampal brain slices. However, the mechanism underlying 
the interaction of A1 and A2A receptors remains to be further explored. Studies have shown 
that selective activation of A2ARs with CGS 21680 generated an attenuation of the A1R 
binding in rat hippocampus (O’Kane and Stone 1998). Since the A2AR agonist CGS 21680 
was shown to decrease the ability of the A1R agonist CPA to inhibit neuronal excitability, 
Cunha’s lab previously proposed that a functional interaction between A1R and A2AR exists 
(Lopes et al. 1999). Whether the A2AR attenuation of A1R binding of CPA or adenosine is a 
result of A1R and A2AR cross talk is still unknown. Preliminary investigations in our lab 
showed that Casein Kinase 2 (CK2), a serine/threonine protein kinase, is downregulated in our 
pial vessel disruption (PVD) stroke model (Chen and Cayabyab, unpublished). Moreover, our 
lab reported that in the PVD stroke model, A1Rs are downregulated after the PVD ischemic 
insult, whereas A2ARs are upregulated (Chen et al. 2014). Considering the fact that CK2 
negatively regulates A2AR desensitization (Rebholz et al. 2009), we hypothesize that CK2 is 
intimately linked to enhancing A2AR surface expression. Future studies are needed to further 
test whether chronic A1R stimulation with CPA mimics the effects of PVD, by causing a 
decreased CK2 expression and, hence, an increased A2AR surface expression. 
 
5.2 Adenosine, adenosine receptors and neuroprotection 
As a neuromodulator, adenosine not only contributes to neuroprotection by inhibiting 
excitatory neurotransmission but it could also mediate neuroprotective intermediary 
metabolism and signalling, which is believed to be the primary mechanism underlying its 
protective effect in non-brain tissue (Cunha 2001). Although A1Rs were commonly recognized 
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as a neuroprotective modulator in the brain, due to the fact that they reduce glutamate release 
and cause neuron hyperpolarization, A1Rs are found to be downregulated in chronic noxious 
conditions. During hypoxia, prolonged stimulation of A1Rs leads to desensitization of A1Rs 
which could underlie the inhibition of synaptic transmission regulated by the internalization of 
A1R. Carvalho’s lab has observed that blockade of A1Rs attenuated the hypoxia-induced 
decrease of energy charge and prevents the recovery of metabolic alterations during the 
normoxic period (Duarte et al. 2016), which is different with the neuroprotective effect I 
observed in the present study. However, the duration of hypoxia is different in their study, in 
which they used a 90-min hypoxia treatment to mimic stroke conditions. Further in vivo studies 
on animal stroke models are needed to determine which kind of hypoxia treatment could more 
accurately represent the human stroke conditions. Currently research in our lab has shown some 
promising results with A1R antagonist’s neuroprotective effect in the PVD stroke model which 
is in line with the observations in the present study. A2AR antagonists have also shown their 
neuroprotective effects in ischemic brain damage and Parkinson’s disease, which has not been 
thoroughly studied in my project. Molecular studies have provided some evidence on the 
involvement of adenosine receptors and metabotropic glutamate type 1 and type 5 receptors in 
neurodegenerative diseases (Canals et al. 2003; Ferre et al. 2002; Nishi et al. 2003), which 
encourages us to further explore the interactions between A1R and A2AR. The mechanisms 
behind how A1R and A2AR control neuroprotection remains to be established in further 
investigations. This project has provided some evidence that the blockade of A1Rs could 
contribute to neuroprotection by regulating synaptic transmission through glutamate receptors, 
i.e., by reducing the expression and function of CP-AMPARs that have been shown in my 
studies to promote neuronal damage. Further studies need to be conducted in adenosine 
receptors’ effects on metabolism and neurogenesis. The potential mechanism between LSP1, 
p38 MAPK and A1R implicated the further crucial role of adenosine receptors in mediating 
neuroinflammation. Even though the complete pathway of adenosine signalling still remains 
unclear, it is evident to suggest that targeting adenosine receptors will provide a novel strategy 
for the treatment of multiple neurological disorders. 
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5.3. Potential therapeutic target for stroke 
Clinical trials for direct antagonism of the NMDAR as a stroke therapeutic target have been 
disappointing. Two main reasons have been pointed out in recent studies. One is that some 
NMDAR antagonists interfere with some important physiological NMDAR functions (Roesler 
et al. 2003), while other major reason is that most of the agents have a narrow therapeutic 
window (Ikonomidou and Turski 2002). The unsuccessful translation of neuroprotective drugs 
from bench to bed side for patients suffering from ischemic stroke over the years has strongly 
suggested that new strategies are eagerly required for both animal stroke models and in the 
clinical realm. Researches have suggested that AMPA receptors have a more significant effect 
in neurodegeneration process of hippocampal CA1 neurons than NMDARs (Buchan et al. 1993; 
Chang et al. 2012; Noh et al. 2005; Schielke et al. 1999). According to electrophysiological 
studies (Buldakova et al. 2007), Ca2+-permeable AMPAR antagonists increased synaptic 
transmission at Schaffer collateral to CA1 region during hypoxic conditions. Moreover, some 
blockers selective for Ca2+-permeable AMPARs, such as IEM 1460, have been shown to 
substantially reduce post ischemic neurodegeneration in the CA1 region, which strongly 
indicates a crucial role for Ca2+-permeable receptors as a potential therapeutic target for treating 
delayed neuronal death after hypoxic-ischemia insult (Schlesinger et al. 2005; Xiong et al. 
2009). In my current research project, some Ca2+-permeable AMPAR antagonists have not 
shown significant neuroprotective effects when administered after the hypoxic insult, which is 
consistent with the suggestion that drugs based on this mechanism failed in clinical trials. 
However, Perampanel, the clinically approved drug used for treating partial seizures and 
generalized seizures for people older than 12 years old is showing beneficial effects when 
applied both during hypoxia and post-hypoxic conditions. It is intriguing to find out why 
Perampanel is having a different effect on post-hypoxia potentiation when compared to other 
AMPAR antagonists. One possible reason is that Perampanel increases GABAAR-mediated 
inhibitory neurotransmission in the rat hippocampus by a mechanism which is not mediated by 
AMPARs and kainate receptors. Studies on GABA receptor regulated synaptic transmission in 
the cerebellum observed that CNQX, a commonly used non-NMDA receptor antagonist, can 
lead to the up-regulation of inhibitory post synaptic currents (IPSCs) (Brickley et al. 2001). 
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Interestingly, GYKI 52466, an relatively more selective AMPA receptor antagonist produced 
no increase in IPSC frequency (Wilding and Huettner 1995).  Since higher dosage (3 µM) of 
Perampanel could also completely block synaptic transmission in the stratum radiatum of the 
CA1 region (Rogawski and Hanada, 2013; also confirmed in our lab, data not shown), which 
is similar to my results with CNQX which completely prevented the baseline fEPSPs and 
APSPs, it is plausible to suggest that Perampanel could also be mediating an allosteric 
modulation of GABAAR-mediated synaptic transmission. Ongoing investigations in our lab 
have already started to test whether Perampanel’s neuroprotective effects on the post-hypoxia 
neuronal damage can be prevented when GABAAR-mediated inhibitory postsynaptic 
transmission is blocked by Bicuculline. The core structure of Perampanel has a 2,3’-bipyridin-
6’-one, which could be a distinguishing feature of Perampanel from other AMPA receptor 
antagonist classes (Rogawski and Hanada 2013); this core structure could account for its 
stronger neuroprotective effects over other AMPAR inhibitors during hypoxic/ischemic brain 
damage. 
 
5.4 Distinguish among different AMPAR subtypes.  
Diversity in the functional AMPAR subtypes have shown their importance in regulating 
AMPAR signalling in the CNS. In my current study, I applied three different kinds of Ca2+ 
permeable AMPAR antagonists. However, in order to elucidate whether there is a GluA1-
containing AMPAR re-insertion during the reperfusion period which leads to different 
neuroprotective effects, better research tools are needed to distinguish GluA1-containing 
AMPARs and GluA3-containing AMPARs. In early observations, researchers reported that 
Philanthotoxin 74, when tested at concentrations of 100 and 500 µM, blocked 80% of 
GluA1/GluA2 AMPARs but only blocked 10% of GluA2/GluA3 AMPARs (Nilsen and 
England 2007). This study suggested that Philanthotoxin-74’s potential role in distinguishing 
different combination of subtypes among AMPAR populations. However, conflicting results 
have been reported in Poulsen’s lab, showing that the marginal influence of the AMPAR 
subunits affects the affinity of Philanthotoxin-74, which might lead to difficulties in 
distinguishing their functional differences. (Poulsen et al. 2013). At present, the best way to 
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investigate changes in GluA1-containing AMPARs is through biochemical methods. Although 
I provided some preliminary biochemical evidence that GluA2 surface expression could be 
altered in different ways depending on the time of exposure to A1R agonists in vivo, clearly 
more studies and other biochemical/molecular tools will be needed to address whether different 
classes of AMPAR antagonists can differentially affect the subunit compositions of functional 
AMPARs in normal and hypoxic/ischemic conditions. 
 
5.5 Kainate receptor in synaptic transmission 
Another important glutamate receptor that has not been researched in this study is kainate 
receptor. Since numerous AMPAR agonists and antagonists can also interact with the kainate 
receptors, AMPARs and kainate receptors are commonly classified by scientists as non-
NMDA receptors. According to the current knowledge of kainate receptors in the 
neuroscience field. The roles for kainate receptors in physiological process for 
neurotransmission have been poorly studied, due to the deficiency of selective antagonist and 
agonist of kainate receptors. Studies showed that GYKI 53655 can antagonize AMPARs, 
while it had no significant effect on kainate receptors (Wilding and Huettner 1995). With the 
application of GYKI 53655, scientists have revealed that certain synaptic responses during 
the interaction between hippocampal CA1 region and Schaffer collaterals are mediated by 
kainate receptors (Frerking et al. 1998). Application of kainate has been shown to reverse the 
suppression of EPSPs and EPSCs in CA1 (Kamiya and Ozawa 1998). These results have 
suggested that kainate receptors have a widely expression in the CNS and may have 
significant functions in mediating synaptic functions. Whether these kainate receptors are 
similarly regulated by A1R and A2AR signalling remains to be established. 
 
5.6 Ca2+-permeable AMPAR trafficking.  
Ca2+-permeable AMPARs have now shown their importance in synaptic transmission and 
synaptic plasticity, due to the observation of the rapid subunit-specific trafficking of synaptic 
AMPAR. The trafficking of AMPARs have been well studied, however, little research has been 
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conducted on CP-AMPARs. Researches have already shown the importance of GluA1-
dependent mechanisms on the LTP expression. In this project, I have indicated the relationship 
between AMPARs and the level of LTP. Meanwhile, in the electrophysiology studies, I 
hypothesis the insertion of CP-AMPARs to the cell surface during the washout period. 
Although LTP were commonly considered as GluA1-dependent, there is still a possibility that 
insertion of CP-AMPARs contributes to other forms of synaptic plasticity. Moreover, it is 
essential to investigate the upstream activities of different AMPAR subunits, and the 
interactions between AMPAR accessory proteins with CP-AMPAR expression. The importance 
of CP-AMPAR is not only evident in the hippocampal neurons, but also in the lateral amygdala, 
due to their similarities in CP-AMPAR trafficking. The present findings of CP-AMPAR’s 
crucial role in the hippocampus may further implicate the roles of adenosine-mediated CP-
AMPAR induction and abnormal AMPAR functions in drug addiction, depression, short term 
memory loss and their potential therapeutic role in brain ischemia. Further investigation on the 
mechanisms of the observation at synapses might uncover potential therapeutic targets. The 
most valuable findings in this study are that late Perampanel administration significantly 
prevents the APSP and other CP-AMPAR blockers like NAPSM and IEM 1460 will also 
provide neuroprotection when applied at the time of the hypoxic insult. These findings suggest 
the GluA2-lacking AMPARs that are expressed at CA1 synapses during chronic phases of 
ischemia, do having a significant effect in neurodegeneration in the rat hippocampal CA1. 
Additionally, my results also suggest that to increase neuroprotection, an early intervention 
with Perampanel can block the majority of GluA2-lacking AMPARs. GluA2-lacking AMPARs 
are normally having a relatively low expression in the rat hippocampal slices in most conditions, 
but their surface expression can be dramatically enhanced during reperfusion. CP-AMPARs 
are also suggested to be associated with other neurological disorders and brain insults. In the 
past decade, researchers have implicated CP-AMPARs as having important roles in seizures 
(Rogawski and Hanada 2013), Alzheimer’s and Parkinson’s disease (Cunha 2005; Whitehead 
et al. 2017). My study in this area has provided further evidence for CP-AMPAR’s involvement 
in hypoxia-induced delayed neuronal death in the hippocampal brain region and suggests that 
the application of CP-AMPAR antagonists need to be revisited as some agents, like Perampanel, 
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could eventually lead to an effective treatment in post-stoke neuronal injury and other 
neurological disorders.   
 
5.7 LSP1, p38 MAPK and synaptic plasticity 
In early studies, scientist have shown that p38 MAPK signalling is important for the induction 
of synaptic plasticity through the induction of NMDAR-induced long term depression (LTD) 
and mGluR-induced LTD. (Thomas et al. 2004; Collingridge et al. 2010). mGluR-induced LTD 
is depending on the activation of p38 MAPK. In previous studies (Chen et al. 2014; Stockwell 
et al. 2016), our lab has shown that stimulation of A1R can lead to the activation of p38 MAPK, 
which then leads to the internalization of GluA2 and GluA1. This could suggest a potential 
mechanism for p38 MAPK-dependent mGluR-induced LTD. However, the direct downstream 
target of p38 MAPK underlying LTD still needs to be investigated. Base on the fact that LSP1 
serves as a important downstream substrate of p38 MAPK and the observed deficiency of LSP1 
in LSP1 knockout mice causing LTP deficits in the present study, it is reasonable to suggest 
that LSP1 is also affecting in this mGluR-induced LTD. When comparing the results from 
mouse and rat cLTP studies in this project, I observed a decreased level of LTP in mouse 
hippocampal slices after the induction of LTP. Some labs have suggested an age-related 
developmental loss of LTP in mouse visual cortex, (Kirkwood et al. 1997; Yoshimura et al 
2003), which may underlie this deficiency of LTP in 12-15 week old mice. Since mouse 
hippocampal slices are much smaller than those of rats, and I used the same bi-polar stimulation 
electrode for rat and mouse studies, the difference in the results I observed in mouse and rats 
(and those of others) might due to inaccurately stimulating the mouse CA1 region. Further 
studies are needed to explain this decrease of synaptic transmission after the induction of LTP. 
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6. Conclusion 
Both adenosine A1Rs and A2ARs are involved in the post-hypoxia potentiation, which 
indicates delayed neuronal death in the hippocampus induced by hypoxic insult. Post-hypoxia 
neurotransmission in the rat CA1 hippocampus is mostly regulated by AMPA-ergic receptors, 
instead of NMDA receptors. 
A priority of this investigation was to identify the effects of glutamate receptors in order to find 
out potential therapeutic targets for ischemic stroke. Similar to NMDAR antagonists, Ca2+-
permeable AMPAR blockers in this study are only effective when applied at the early stage of 
insult. Perampanel, on the other hand, could potentially provide neuroprotection in hypoxic 
conditions, and could potentially be effective even during ischemia/reperfusion periods. 
Further studies aimed at determining how Perampanel mediates this increased neuroprotection 
are warranted, including studies of levels of neuroinflammation, levels of reactive oxygen 
production, and levels of Ca2+-induced excitotoxicity.    
LTP impairment occurs when global activation of A1R is induced, which can be countered by 
A1R antagonists. The mechanisms underlying A1R-mediated AMPAR endocytosis and 
synaptic plasticity changes still need further investigation. Adenosine signalling, and the 
different glutamate receptor functions studied in this project, may ultimately provide a more 
comprehensive understanding as a basis for an effective rationale to investigate and identify 
future therapeutic strategies for ischemic stroke.  
 
 
 
 
 
 
 
75 
 
References 
Ahmadian, Gholamreza et al. 2004. “Tyrosine Phosphorylation of GluR2 Is Required for 
Insulin-Stimulated AMPA Receptor Endocytosis and LTD.” EMBO Journal 23(5):1040–
50. 
Albers, G. W. et al. 1999. “Dose Escalation Study of the NMDA Glycine-Site Antagonist 
Licostinel in Acute Ischemic Stroke.” Stroke 30(3):508–13. 
Almeida, T., R. J. Rodrigues, A. De Mendonça, J. A. Ribeiro, and R. A. Cunha. 2003. 
“Purinergic P2 Receptors Trigger Adenosine Release Leading to Adenosine A2Areceptor 
Activation and Facilitation of Long-Term Potentiation in Rat Hippocampal Slices.” 
Neuroscience 122(1):111–21. 
Annunziato, Lucio, Mauro Cataldi, Giuseppe Pignataro, Agnese Secondo, and Pasquale 
Molinaro. 2007. “Glutamate-Independent Calcium Toxicity: Introduction.” Pp. 661–64 in 
Stroke, vol. 38. 
Anon. n.d. “HS_StrokeReport2017_EN.” 
Anzai, Takeshi et al. 2003. “Overexpression of Ca2+-Permeable AMPA Receptor Promotes 
Delayed Cell Death of Hippocampal CA1 Neurons Following Transient Forebrain 
Ischemia.” Neuroscience Research 46(1):41–51. 
Berridge, Michael J. 2011. “Calcium Signalling and Alzheimer’s Disease.” Neurochemical 
Research 36(7):1149–56. 
Brickley, S. G., M. Farrant, G. T. Swanson, and S. G. Cull-Candy. 2001. “CNQX Increases 
GABA-Mediated Synaptic Transmission in the Cerebellum by an AMPA/kainate 
Receptor-Independent Mechanism.” Neuropharmacology 41(6):730–36. 
Brust, Tyson B., Francisco S. Cayabyab, and Brian A. MacVicar. 2007. “C-Jun N-Terminal 
Kinase Regulates Adenosine A1 Receptor-Mediated Synaptic Depression in the Rat 
Hippocampus.” Neuropharmacology 53(8):906–17. 
Buchan, A. M. et al. 1993. “AMPA Antagonists: Do They Hold More Promise for Clinical 
76 
 
Stroke Trials than NMDA  Antagonists?” Stroke; a Journal of Cerebral Circulation 
24(12 Suppl):I148-52. 
Buldakova, S. L., K. K. Kim, D. B. Tikhonov, and L. G. Magazanik. 2007. “Selective Blockade 
of Ca2+ Permeable AMPA Receptors in CA1 Area of Rat Hippocampus.” Neuroscience 
144(1):88–99. 
Canals, Meritxell et al. 2003. “Homodimerization of Adenosine A2A Receptors: Qualitative 
and Quantitative Assessment by Fluorescence and Bioluminescence Energy Transfer.” 
Journal of Neurochemistry 88(3):726–34. 
Casetta, I. et al. 2014. “A2A Adenosine Receptors and Parkinson’s Disease Severity.” Acta 
Neurologica Scandinavica 129(4):276–81. 
Chang, Philip K. Y., David Verbich, and R.Anne McKinney. 2012. “AMPA Receptors as Drug 
Targets in Neurological Disease--Advantages, Caveats, and Future Outlook.” The 
European Journal of Neuroscience 35(12):1908–16. 
Chen, Z. C. et al. 2014. “Prolonged Adenosine A1 Receptor Activation in Hypoxia and Pial 
Vessel Disruption Focal Cortical Ischemia Facilitates Clathrin-Mediated AMPA Receptor 
Endocytosis and Long-Lasting Synaptic Inhibition in Rat Hippocampal CA3-CA1 
Synapses: Differential Regulat.” Journal Of Neuroscience 34(29):9621–43. 
Chen, Zhicheng, Jocelyn Stockwell, and Francisco S. Cayabyab. 2016. “Adenosine A1 
Receptor-Mediated Endocytosis of AMPA Receptors Contributes to Impairments in Long-
Term Potentiation (LTP) in the Middle-Aged Rat Hippocampus.” Neurochemical 
Research 41(5):1085–97. 
Collingridge, Graham L., Stephane Peineau, John G. Howland, and Yu Tian Wang. 2010. 
“Long-Term Depression in the CNS.” Nature Reviews Neuroscience 11(7):459–73. 
Constals, Audrey et al. 2015. “Glutamate-Induced AMPA Receptor Desensitization Increases 
Their Mobility and Modulates Short-Term Plasticity through Unbinding from Stargazin.” 
Neuron 85(4):787–803. 
Cooper, Janine M. et al. 2015. “Neonatal Hypoxia, Hippocampal Atrophy, and Memory 
77 
 
Impairment: Evidence of a Causal Sequence.” Cerebral Cortex 25(6):1469–76. 
Cunha, R. A. 2001. “Adenosine as a Neuromodulator and as a Homeostatic Regulator in the 
Nervous System: Different Roles, Different Sources and Different Receptors.” 
Neurochemistry International 38(2):107–25. 
Cunha, Rodrigo A. 2005. “Neuroprotection by Adenosine in the Brain: From A1 Receptor 
Activation to A2A Receptor Blockade.” Purinergic Signalling 1(2):111–34. 
Davis, S. M. et al. 2000. “Selfotel in Acute Ischemic Stroke : Possible Neurotoxic Effects of an 
NMDA Antagonist.” Stroke 31(2):347–54. 
Dhawan, J. et al. 2011. “A New Look at Glutamate and Ischemia: NMDA Agonist Improves 
Long-Term Functional Outcome in a Rat Model of Stroke.” Future Neurol 6(6):823–34. 
Dong, Xiao Xia, Yan Wang, and Zheng Hong Qin. 2009. “Molecular Mechanisms of 
Excitotoxicity and Their Relevance to Pathogenesis of Neurodegenerative Diseases.” Acta 
Pharmacologica Sinica 30(4):379–87. 
Dong, Zhifang et al. 2015. “Long-Term Potentiation Decay and Memory Loss Are Mediated 
by AMPAR Endocytosis.” Journal of Clinical Investigation 125(1):234–47. 
Duarte, João M. N., Rodrigo A. Cunha, and Rui A. Carvalho. 2016. “Adenosine A 1 Receptors 
Control the Metabolic Recovery after Hypoxia in Rat Hippocampal Slices.” Journal of 
Neurochemistry 136(5):947–57. 
Ferdinand, Phillip and Christine Roffe. 2016. “Hypoxia after Stroke: A Review of Experimental 
and Clinical Evidence.” Experimental & Translational Stroke Medicine 8(1):9. 
Ferre, S. et al. 2002. “Synergistic Interaction between Adenosine A2A and Glutamate mGlu5 
Receptors: Implications for Striatal Neuronal Function.” Proceedings of the National 
Academy of Sciences 99(18):11940–45. 
Filliat, Pierre, Irmine Pernot-Marino, Dominique Baubichon, and Guy Lallement. 1998. 
“Behavioral Effects of NBQX, a Competitive Antagonist of the AMPA Receptors.” 
Pharmacology Biochemistry and Behavior 59(4):1087–92. 
78 
 
Frampton, James E. 2015. “Perampanel: A Review in Drug-Resistant Epilepsy.” Drugs 
75(14):1657–68. 
Frerking, M., R. C. Malenka, and R. a Nicoll. 1998. “Synaptic Activation of Kainate Receptors 
on Hippocampal Interneurons.” Nature Neuroscience 1(6):479–86. 
Garcia, Neus et al. 2014. “Adenosine A2B and A3 Receptor Location at the Mouse 
Neuromuscular Junction.” Journal of Anatomy 225(1):109–17. 
Ginsberg, Myron D. 2009. “Current Status of Neuroprotection for Cerebral Ischemia Synoptic 
Overview.” in Stroke, vol. 40. 
Gomes, C. V., M. P. Kaster, A. R. Tomé, P. M. Agostinho, and R. A. Cunha. 2011. “Adenosine 
Receptors and Brain Diseases: Neuroprotection and Neurodegeneration.” Biochimica et 
Biophysica Acta 1808(5):1380–99. 
Gooshe, Maziar et al. 2015. “Hypoxia/ischemia a Key Player in Early Post Stroke Seizures: 
Modulation by Opioidergic and Nitrergic Systems.” European Journal of Pharmacology 
746:6–13. 
Greenfield, L.John. 2013. “Molecular Mechanisms of Antiseizure Drug Activity at GABAA 
Receptors.” Seizure 22(8):589–600. 
Hiu, Takeshi et al. 2016. “Enhanced Phasic GABA Inhibition during the Repair Phase of Stroke: 
A Novel Therapeutic Target.” Brain 139(2):468–80. 
Howard, R. S., P. A. Holmes, and M. A. Koutroumanidis. 2011. “Hypoxic-Ischaemic Brain 
Injury.” Practical Neurology 11(1):4–18. 
Hoyte, L., P. Barber, A. Buchan, and M. Hill. 2004. “The Rise and Fall of NMDA Antagonists 
for Ischemic Stroke.” Current Molecular Medicine 4(2):131–36. 
Huang, Zhi Li, Ze Zhang, and Wei Min Qu. 2014. “Roles of Adenosine and Its Receptors in 
Sleep-Wake Regulation.” International Review of Neurobiology 119:349–71. 
Hung, Ivan F. N. et al. 2017. “Unexpectedly Higher Morbidity and Mortality of Hospitalized 
Elderly Patients Associated with Rhinovirus Compared with Influenza Virus Respiratory 
79 
 
Tract Infection.” International Journal of Molecular Sciences 18(2):259.  
Hunt, David L. and Pablo E. Castillo. 2012. “Synaptic Plasticity of NMDA Receptors: 
Mechanisms and Functional Implications.” Current Opinion in Neurobiology 22(3):496–
508. 
Ikonomidou, Chrysanthy, Yueqin Qin, Joann Labruyere, Charity Kirby, and John W. Olney. 
1996. “Prevention of Trauma-Induced Neurodegeneration in Infant Rat Brain.” Pediatric 
Research 39(6):1020–27. 
Ikonomidou, Chrysanthy and Lechoslaw Turski. 2002. “Why Did NMDA Receptor 
Antagonists Fail Clinical Trials for Stroke and Traumatic Brain Injury?” Lancet Neurology 
1(6):383–86. 
Jo, Seonmi et al. 2014. “GABA from Reactive Astrocytes Impairs Memory in Mouse Models 
of Alzheimer’s Disease.” Nature Medicine 20(8):886–96. 
Kamiya, H. and S. Ozawa. 1998. “Kainate Receptor-Mediated Inhibition of Presynaptic Ca2+ 
Influx and EPSP in Area CA1 of the Rat Hippocampus.” The Journal of Physiology 509 
( Pt 3:833–45. 
Kirkwood, A. A., A. A. Silva, and M. F. M. F. Bear. 1997. “Age-Dependent Decrease of 
Synaptic Plasticity in the Neocortex of alphaCaMKII Mutant Mice.” Proceedings of the 
National Academy of Sciences 94(7):3380–83. 
Kitagawa, Hisashi, Atsushi Mori, Jun Shimada, Yasuhide Mitsumoto, and Tetsuro Kikuchi. 
2002. “Intracerebral Adenosine Infusion Improves Neurological Outcome after Transient 
Focal Ischemia in Rats.” Neurological Research 24:317–23. 
Komiyama, Takaaki et al. 2015. “Does Moderate Hypoxia Alter Working Memory and 
Executive Function during Prolonged Exercise?” Physiology and Behavior 139:290–96. 
Kostandy, Botros B. 2012. “The Role of Glutamate in Neuronal Ischemic Injury: The Role of 
Spark in Fire.” Neurological Sciences 33(2):223–37. 
Lai, Ted Weita, Shu Zhang, and Yu Tian Wang. 2014. “Excitotoxicity and Stroke: Identifying 
80 
 
Novel Targets for Neuroprotection.” Progress in Neurobiology 115(C):157–88. 
Latini, Serena, Francesca Bordoni, Félicita Pedata, and Renato Corradetti. 1999. “Extracellular 
Adenosine Concentrations during in Vitro Ischaemia in Rat Hippocampal Slices.” British 
Journal of Pharmacology 127(3):729–39. 
Lau, Anthony and Michael Tymianski. 2010. “Glutamate Receptors, Neurotoxicity and 
Neurodegeneration.” Pflugers Archiv European Journal of Physiology 460(2):525–42. 
Layland, Jamie, David Carrick, Matthew Lee, Keith Oldroyd, and Colin Berry. 2014. 
“Adenosine: Physiology, Pharmacology, and Clinical Applications.” JACC: 
Cardiovascular Interventions 7(6):581–91. 
Le, Nguyen Phuong Khanh, Shankaramurthy Channabasappa, Mokarram Hossain, Lixin Liu, 
and Baljit Singh. 2015. “Leukocyte-Specific Protein 1 Regulates Neutrophil Recruitment 
in Acute Lung Inflammation.” American Journal of Physiology - Lung Cellular and 
Molecular Physiology 309(9):L995–1008. 
Lee, Sang Hyoung, Alyson Simonetta, and Morgan Sheng. 2004. “Subunit Rules Governing 
the Sorting of Internalized AMPA Receptors in Hippocampal Neurons.” Neuron 
43(2):221–36. 
de Lera Ruiz, Manuel, Yeon-hee Lim, and Junying Zheng. 2014. “Adenosine A2A Receptor as 
a Drug Discovery Target.” Journal of Medicinal Chemistry 57(9):3623–50. 
Lipton, Stuart A. 2004. “Failures and Successes of NMDA Receptor Antagonists: Molecular 
Basis for the Use of Open-Channel Blockers like Memantine in the Treatment of Acute 
and Chronic Neurologic Insults.” NeuroRx 1(1):101–10. 
Liu, Lixin et al. 2005. “LSP1 Is an Endothelial Gatekeeper of Leukocyte Transendothelial 
Migration.” The Journal of Experimental Medicine 201(3):409–18. 
Liu, Shu Hong et al. 2004. “Expression of Ca2+-Permeable AMPA Receptor Channels Primes 
Cell Death in Transient Forebrain Ischemia.” Neuron 43(1):43–55. 
Lopes, L. V, R. A. Cunha, and J. A. Ribeiro. 1999. “Cross Talk between A(1) and A(2A) 
81 
 
Adenosine Receptors in the Hippocampus and Cortex of Young Adult and Old Rats.” 
Journal of Neurophysiology 82(6):3196–3203. 
Lu, Wei et al. 2009. “Subunit Composition of Synaptic AMPA Receptors Revealed by a Single-
Cell Genetic Approach.” Neuron 62(2):254–68. 
von Lubitz, D. K. 1999. “Adenosine and Cerebral Ischemia: Therapeutic Future or Death of a 
Brave Concept?” European Journal of Pharmacology 371(1):85–102. 
Luscher, Bernhard, Thomas Fuchs, and Casey L. Kilpatrick. 2011. “GABAA Receptor 
Trafficking-Mediated Plasticity of Inhibitory Synapses.” Neuron 70(3):385–409.  
Macia, Eric et al. 2006. “Dynasore, a Cell-Permeable Inhibitor of Dynamin.” Developmental 
Cell 10(6):839–50. 
Manjunath, S. and PranavkumarM Sakhare. 2009. “Adenosine and Adenosine Receptors: 
Newer Therapeutic Perspective.” Indian Journal of Pharmacology 41(3):97. 
Matute, Carlos, Maria Domercq, and Maria-Victoria Sanchez-Gomez. 2006. “Glutamate-
Mediated Glial Injury: Mechanisms and Clinical Importance.” Glia 53(2):212–24. 
Maximino, Caio, Monica G. Lima, Karen R. M. Olivera, Domingos L. W. Picanço-Diniz, and 
Anderson M. Herculano. 2011. “Adenosine A1, but Not A2, Receptor Blockade Increases 
Anxiety and Arousal in Zebrafish.” Basic and Clinical Pharmacology and Toxicology 
109(3):203–7. 
Meden, Per, Karsten Overgaard, Tomas Sereghy, and Gudrun Boysen. 1993. “Enhancing the 
Efficacy of Thrombolysis by AMPA Receptor Blockade with NBQX in a Rat Embolic 
Stroke Model.” Journal of the Neurological Sciences 119(2):209–16. 
Meldrum, B. 1990. “Protection against Ischaemic Neuronal Damage by Drugs Acting on 
Excitatory Neurotransmission.” Cerebrovasc.Brain Metab Rev. 2(1040–8827 (Print)):27–
57. 
De Mendonça, A. and J. A. Ribeiro. 1994. “Endogenous Adenosine Modulates Long-Term 
Potentiation in the Hippocampus.” Neuroscience 62(2):385–90. 
82 
 
De Mendonça, Alexandre and Joachim A. Ribeiro. 2001. “Adenosine and Synaptic Plasticity.” 
Pp. 283–90 in Drug Development Research, vol. 52. 
Moretti, Antonio, Federica Ferrari, and Roberto F. Villa. 2015. “Neuroprotection for Ischaemic 
Stroke: Current Status and Challenges.” Pharmacology & Therapeutics 146:23–34.  
Nakav, Sigal et al. 2008. “Anti-Inflammatory Preconditioning by Agonists of Adenosine A1 
Receptor.” PLoS ONE 3(5). 
Nayak, P. K. and D. S. Kerr. 2013. “Low-Dose GYKI-52466: Prophylactic Preconditioning 
Confers Long-Term Neuroprotection and Functional Recovery Following Hypoxic-
Ischaemic Brain Injury.” Neuroscience 232:128–38. 
Nilsen, Aaron and Pamela M. England. 2007. “A Subtype-Selective, Use-Dependent Inhibitor 
of Native AMPA Receptors.” Journal of the American Chemical Society 129(16):4902–3. 
Nishi, Akinori et al. 2003. “Metabotropic mGlu5 Receptors Regulate Adenosine A2A Receptor 
Signaling.” Proceedings of the National Academy of Sciences of the United States of 
America 100(3):1322–27. 
Noh, Kyung-Min et al. 2005. “Blockade of Calcium-Permeable AMPA Receptors Protects 
Hippocampal Neurons against Global Ischemia-Induced Death.” Proceedings of the 
National Academy of Sciences of the United States of America 102(34):12230–35.  
O’Kane, E. M. and T. W. Stone. 1998. “Interaction between Adenosine A1 and A2 Receptor-
Mediated Responses in the Rat Hippocampus in Vitro.” European Journal of 
Pharmacology 362(1):17–25.  
Olsson, Tomas et al. 2004. “Deletion of the Adenosine A1 Receptor Gene Does Not Alter 
Neuronal Damage Following Ischaemia in Vivo or in Vitro.” European Journal of 
Neuroscience 20(5):1197–1204. 
Pardridge, W. M., T. Yoshikawa, Y. S. Kang, and L. P. Miller. 1994. “Blood-Brain Barrier 
Transport and Brain Metabolism of Adenosine and Adenosine Analogs.” The Journal of 
Pharmacology and Experimental Therapeutics 268(1):14–18. 
83 
 
Patel, Nandini C. 2015. “Perampanel (Fycompa): AMPA Receptor Antagonist for the 
Treatment of Seizure.” Pp. 271–82 in Innovative Drug Synthesis. 
Paternain, Ana V., Miguel Morales, and Juan Lerma. 1995. “Selective Antagonism of AMPA 
Receptors Unmasks Kainate Receptor-Mediated Responses in Hippocampal Neurons.” 
Neuron 14(1):185–89. 
Paterniti, Irene et al. 2011. “Selective Adenosine A2A Receptor Agonists and Antagonists 
Protect against Spinal Cord Injury through Peripheral and Central Effects.” Journal of 
Neuroinflammation 8(1):31. 
Payabvash, Seyedmehdi et al. 2011. “Regional Ischemic Vulnerability of the Brain to 
Hypoperfusion: The Need for Location Specific Computed Tomography Perfusion 
Thresholds in Acute Stroke Patients.” Stroke 42(5):1255–60. 
Pedata, Felicita et al. 2007. “The Role of ATP and Adenosine in the Brain under Normoxic and 
Ischemic Conditions.” Purinergic Signalling 3(4):299–310. 
Porkka-Heiskanen, Tarja and Anna V. Kalinchuk. 2011. “Adenosine, Energy Metabolism and 
Sleep Homeostasis.” Sleep Medicine Reviews 15(2):123–35. 
Poulsen, M. H., S. Lucas, K. Stromgaard, and A. S. Kristensen. 2013. “Evaluation of PhTX-74 
as Subtype-Selective Inhibitor of GluA2-Containing AMPA Receptors.” Molecular 
Pharmacology 85(2):261–68. 
Pugliese, a M. et al. 2009. “The Adenosine A2A Receptor Antagonist ZM241385 Enhances 
Neuronal Survival after Oxygen-Glucose Deprivation in Rat CA1 Hippocampal Slices.” 
British Journal of Pharmacology 157(5):818–30. 
Rebholz, Heike et al. 2009. “CK2 Negatively Regulates Galphas Signaling.” Proceedings of 
the National Academy of Sciences of the United States of America 106(33):14096–101.  
Reyhani-Rad, Siamak and Javad Mahmoudi. 2016. “Effect of Adenosine A2A Receptor 
Antagonists on Motor Disorders Induced by 6-Hydroxydopamine in Rat.” Acta Cirurgica 
Brasileira 31(2):133–37. 
84 
 
Ribeiro, Fabiola M., Maryse Paquet, Sean P. Cregan, and Stephen S. G. Ferguson. 2010. 
“Group I Metabotropic Glutamate Receptor Signalling and Its Implication in Neurological 
Disease.” CNS & Neurological Disorders Drug Targets 9(5):574–95. 
Ribeiro, Joaquim A. and Ana M. Sebastio. 2010. “Caffeine and Adenosine.” in Journal of 
Alzheimer’s Disease, vol. 20. 
Roesler, Rafael, João Quevedo, Nadja Schröder, Chrysanthy Ikonomidou, and Lechoslaw 
Turski. 2003. “Is It Time to Conclude That NMDA Antagonists Have Failed? (Multiple 
Letters).” Lancet Neurology 2(1):13. 
Rogawski, M. A. and T. Hanada. 2013. “Preclinical Pharmacology of Perampanel, a Selective 
Non-Competitive AMPA Receptor Antagonist.” Acta Neurologica Scandinavica 
127(SUPPL.197):19–24. 
Rohracher, A. et al. 2015. “Perampanel in Patients with Refractory and Super-Refractory Status 
Epilepticus in a Neurological Intensive Care Unit.” Epilepsy and Behavior 49:354–58. 
Rudolph, Uwe and Hanns Möhler. 2014. “GABAA Receptor Subtypes: Therapeutic Potential 
in Down Syndrome, Affective Disorders, Schizophrenia, and Autism.” Annual Review of 
Pharmacology and Toxicology 54(1):483–507. 
Schauwecker, Paula Elyse. 2010. “Neuroprotection by Glutamate Receptor Antagonists against 
Seizure-Induced Excitotoxic Cell Death in the Aging Brain.” Experimental Neurology 
224(1):207–18. 
Schielke, G. P. et al. 1999. “The Neuroprotective Effect of the Novel AMPA Receptor 
Antagonist PD152247 (PNQX) in Temporary Focal Ischemia in the Rat.” Stroke 
30(7):1472–77.  
Schlesinger, Friedrich, Derk Tammena, Klaus Krampfl, and Johannes Bufler. 2005. “Two 
Mechanisms of Action of the Adamantane Derivative IEM-1460 at Human AMPA-Type 
Glutamate Receptors.” British Journal of Pharmacology 145(5):656–63. 
Schwartz-Bloom, R. D. and R. Sah. 2001. “Gamma-Aminobutyric acid(A) Neurotransmission 
and Cerebral Ischemia.” Journal of Neurochemistry 77(2):353–71. 
85 
 
Sheth, Sandeep, Rafael Brito, Debashree Mukherjea, Leonard P. Rybak, and Vickram 
Ramkumar. 2014. “Adenosine Receptors: Expression, Function and Regulation.” 
International Journal of Molecular Sciences 15(2):2024–52. 
Silver, Ian A. and Maria Erecińska. 1992. “Ion Homeostasis in Rat Brain in Vivo: Intra- and 
Extracellular [Ca 2+ ] and [H + ] in the Hippocampus during Recovery from Short-Term, 
Transient Ischemia.” Journal of Cerebral Blood Flow & Metabolism 12(5):759–72.  
Simon, RP, JH Swan, T. Griffiths, and BS Meldrum. 1984. “Blockade of N-Methyl-D-
Aspartate Receptors May Protect against Ischemic Damage in the Brain.” Science 
226(4676):850–52. 
Sperlágh, Beáta and E.Sylvester Vizi. 2011. “The Role of Extracellular Adenosine in Chemical 
Neurotransmission in the Hippocampus and Basal Ganglia: Pharmacological and Clinical 
Aspects.” Current Topics in Medicinal Chemistry 11(8):1034–46. 
Stockwell, Jocelyn, Zhicheng Chen, Mina Niazi, Siddarth Nosib, and Francisco S. Cayabyab. 
2016. “Protein Phosphatase Role in Adenosine A1 Receptor-Induced AMPA Receptor 
Trafficking and Rat Hippocampal Neuronal Damage in Hypoxia/reperfusion Injury.” 
Neuropharmacology 102:254–65. 
Stockwell, Jocelyn, Elisabet Jakova, and Francisco S. Cayabyab. 2017. “Adenosine A1 and 
A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.” 
Molecules 22(4). 
Sweeney, M. I. 1997. “Neuroprotective Effects of Adenosine in Cerebral Ischemia: Window of 
Opportunity.” Neuroscience and Biobehavioral Reviews 21(2):207–17. 
Talos, Delia M. et al. 2006. “Developmental Regulation of Alpha-Amino-3-Hydroxy-5-
Methyl-4-Isoxazole-Propionic Acid Receptor Subunit Expression in Forebrain and 
Relationship to Regional Susceptibility to Hypoxic/ischemic Injury. II. Human Cerebral 
White Matter and Cortex.” The Journal of Comparative Neurology 497(1):61–77.  
Thauerer, Bettina, Stephanie Zur Nedden, and Gabriele Baier-Bitterlich. 2012. “Purine 
Nucleosides: Endogenous Neuroprotectants in Hypoxic Brain.” Journal of 
86 
 
Neurochemistry 121(3):329–42. 
Thomas, Gareth M. and Richard L. Huganir. 2004. “MAPK Cascade Signalling and Synaptic 
Plasticity.” Nature Reviews Neuroscience 5(3):173–83. 
Traynelis, Stephen F. et al. 2010. “Glutamate Receptor Ion Channels: Structure, Regulation, 
and Function.” Pharmacological Reviews 62(3):405–96. 
Tymianski, Michael and Charles H. Tator. 1996. “Normal and Abnormal Calcium Homeostasis 
in Neurons: A Basis for the Pathophysiology of Traumatic and Ischemic Central Nervous 
System Injury.” Neurosurgery 38(6):1176–95. 
Vithlani, Mansi, Miho Terunuma, and Stephen J. Moss. 2011. “The Dynamic Modulation of 
GABA(A) Receptor Trafficking and Its Role in Regulating the Plasticity of Inhibitory 
Synapses.” Physiological Reviews 91(3):1009–22. 
Walther, Tobias C. et al. 2006. “Eisosomes Mark Static Sites of Endocytosis.” Nature 
439(7079):998–1003. 
Weiss, John H. 2011. “Ca2+ Permeable AMPA Channels in Diseases of the Nervous System.” 
Frontiers in Molecular Neuroscience 4(November):1–7. 
Whitehead, Garry, Philip Regan, Daniel J. Whitcomb, and Kwangwook Cho. 2017. “Ca2+-
Permeable AMPA Receptor: A New Perspective on Amyloid-Beta Mediated 
Pathophysiology of Alzheimer’s Disease.” Neuropharmacology 112:221–27. 
Wilding, T. J. and J. E. Huettner. 1995. “Differential Antagonism of Alpha-Amino-3-Hydroxy-
5-Methyl-4- Isoxazolepropionic Acid-Preferring and Kainate-Preferring Receptors by 
2,3-Benzodiazepines.” Molecular Pharmacology 47(3):582–87. 
Williams-Karnesky, Rebecca and Mary Stenzel-Poore. 2009. “Adenosine and Stroke: 
Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute 
Neuroprotectant.” Current Neuropharmacology 7(3):217–27. 
Wright, Amanda and Bryce Vissel. 2012. “The Essential Role of AMPA Receptor GluR2 
Subunit RNA Editing in the Normal and Diseased Brain.” Frontiers in Molecular 
87 
 
Neuroscience 
Xiong, Ye, Asim Mahmood, and Michael Chopp. 2009. “Emerging Treatments for Traumatic 
Brain Injury.” Expert Opinion on Emerging Drugs 14(1):67–84. 
Yoshimura, Yumiko, Tomohisa Ohmura, and Yukio Komatsu. 2003. “Two Forms of Synaptic 
Plasticity with Distinct Dependence on Age, Experience, and NMDA Receptor Subtype 
in Rat Visual Cortex.” The Journal of Neuroscience 23(16):6557. 
Zamanillo, D. et al. 1999. “Importance of AMPA Receptors for Hippocampal Synaptic 
Plasticity but Not for Spatial Learning.” Science 284(5421):1805–11.  
 
